Updated on 2024/02/02

写真a

 
ASADA Noboru
 
Organization
Okayama University Hospital Lecturer
Position
Lecturer
External link

Degree

  • 医学博士 ( 岡山大学 )

Research Interests

  • 自律神経

  • 造血幹細胞ニッチ

  • 造血幹細胞

Research Areas

  • Life Science / Hematology and medical oncology

Education

  • Okayama University     医歯薬学総合研究科

    - 2013.9

      More details

  • Okayama University   医学部   医学科

    - 2003.3

      More details

Research History

  • 岡山大学病院   講師

    2023.7

      More details

  • 岡山大学病院

    2021.11

      More details

  • Okayama University Hospital   Assistant Professor

    2017.4 - 2023.6

      More details

  • Albert Einstein College of Medicine   Postdoctral fellow

    2013.8 - 2017.3

      More details

  • Okayama University Hospital   輸血部

    2009.8 - 2013.8

      More details

  • Okayama University Hospital

    2007.6 - 2008.4

      More details

  • Kameda General Hospital

    2003.4 - 2007.5

      More details

▼display all

Professional Memberships

  • THE JAPANESE SOCIETY FOR REGENERATIVE MEDICINE

      More details

  • 日本造血細胞移植学会

      More details

  • THE JAPANESE SOCIETY OF HEMATOLOGY

      More details

  • THE JAPANESE SOCIETY OF INTERNAL MEDICINE

      More details

  • American Society of Hematology

      More details

  • THE JAPAN SOCIETY OF TRANSFUSION MEDICINE AND CELL THERAPY

      More details

▼display all

 

Papers

  • Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy. Reviewed International journal

    Wataru Kitamura, Noboru Asada, Yusuke Naoi, Masaya Abe, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    British journal of haematology   202 ( 2 )   294 - 307   2023.3

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Mechanisms of prolonged cytopenia (PC) after chimeric antigen receptor (CAR) T-cell therapy, an emerging therapy for relapsed or refractory diffuse large B-cell lymphoma, remain elusive. Haematopoiesis is tightly regulated by the bone marrow (BM) microenvironment, called the 'niche'. To investigate whether alterations in the BM niche cells are associated with PC, we analysed CD271+ stromal cells in BM biopsy specimens and the cytokine profiles of the BM and serum obtained before and on day 28 after CAR T-cell infusion. Imaging analyses of the BM biopsy specimens revealed that CD271+ niche cells were severely impaired after CAR T-cell infusion in patients with PC. Cytokine analyses after CAR T-cell infusion showed that CXC chemokine ligand 12 and stem cell factor, niche factors essential for haematopoietic recovery, were significantly decreased in the BM of patients with PC, suggesting reduced niche cell function. The levels of inflammation-related cytokines on day 28 after CAR T-cell infusion were consistently high in the BM of patients with PC. Thus, we demonstrate for the first time that BM niche disruption and sustained elevation of inflammation-related cytokines in the BM following CAR T-cell infusion are associated with subsequent PC.

    DOI: 10.1111/bjh.18747

    PubMed

    researchmap

  • Recent advances in “sickle and niche” research - Tribute to Dr. Paul S Frenette - Reviewed

    Lidiane S. Torres, Noboru Asada, Mitchell J. Weiss, Andreas Trumpp, Toshio Suda, David T. Scadden, Keisuke Ito

    Stem Cell Reports   17 ( 7 )   1509 - 1535   2022.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.stemcr.2022.06.004

    researchmap

  • Treatment outcomes of IgG4-producing marginal zone B-cell lymphoma: a retrospective case series Reviewed

    Yuichi Sumii, Noboru Asada, Yasuharu Sato, Koh-ichi Ohshima, Masanori Makita, Yusuke Yoshimoto, Yuka Sogabe, Kenji Imajo, Yusuke Meguri, Daisuke Ennishi, Hisakazu Nishimori, Nobuharu Fujii, Ken-ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    International Journal of Hematology   112 ( 6 )   780 - 786   2020.8

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    IgG4-producing marginal zone B-cell lymphomas (MZLs) have been recently proposed as a subtype of MZLs. Despite the abundant literature on pathophysiological features of this type of lymphoma, only a few retrospective studies pertaining to the treatment outcomes have been reported, and its prognosis remains unclear. We retrospectively analyzed seven patients with IgG4-producing MZLs diagnosed at our institute, with specific reference to treatment and outcomes. The median age was 69.0 years (55-79), and all were males. The median follow-up period was 66.6 months (8-121). All patients had localized disease; four patients had tumors of the ocular adnexa, whereas two had retroperitoneal tumors. Five patients were treated with irradiation (30 Gy/15 fr) (n = 4) or surgery (n = 1), resulting in tumor reduction. Two patients were treated by chemotherapy or irradiation. Among them, one commenced rituximab monotherapy, which led to an inadequate reduction of the tumor. Subsequent irradiation induced complete response (CR). The other patient experienced repeated relapses during follow-up and finally achieved CR by combination chemotherapy. Treatment was well tolerated in all cases, and none of the patients showed disease progression at the last follow-up visit. Our results indicate that the standard treatments for MZLs are generally appropriate for IgG4-producing MZL.

    DOI: 10.1007/s12185-020-02968-w

    PubMed

    researchmap

    Other Link: http://link.springer.com/article/10.1007/s12185-020-02968-w/fulltext.html

  • Snai2 Maintains Bone Marrow Niche Cells by Repressing Osteopontin Expression Reviewed

    Qiaozhi Wei, Fumio Nakahara, Noboru Asada, Dachuan Zhang, Xin Gao, Chunliang Xu, Alan Alfieri, N. Patrik Brodin, Samuel E. Zimmerman, Jessica C. Mar, Chandan Guha, Wenjun Guo, Paul S. Frenette

    Developmental Cell   53 ( 5 )   503 - 513.e5   2020.6

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.devcel.2020.04.012

    researchmap

  • Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11 Reviewed International journal

    Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta, Isamu Sugiura, Masashi Sawa, Nobuaki Dobashi, Hisayuki Yokoyama, Noriko Doki, Akihiro Tomita, Toru Kiguchi, Shiro Koh, Heiwa Kanamori, Noriyoshi Iriyama, Akio Kohno, Yukiyoshi Moriuchi, Noboru Asada, Daiki Hirano, Kazuto Togitani, Toru Sakura, Maki Hagihara, Tatsuki Tomikawa, Yasuhisa Yokoyama, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi

    Blood Advances   4 ( 1 )   66 - 75   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:American Society of Hematology  

    <title>Key Points</title>
    KIT exon 17 mutation is a poor prognostic factor in AML patients with RUNX1-RUNX1T1, but not in those with CBFB-MYH11. NRAS mutation is a poor prognostic factor in AML patients with CBFB-MYH11.

    DOI: 10.1182/bloodadvances.2019000709

    PubMed

    researchmap

  • Adult T-cell Leukemia-lymphoma with Primary Breast Involvement: A Case Report and Literature Review Reviewed

    Hiroki Kobayashi, Noboru Asada, Takuro Igawa, Masaya Abe, Yusuke Meguri, Daisuke Ennishi, Hisakazu Nishimori, Nobuharu Fujii, Ken-ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    Internal Medicine   59 ( 21 )   2757 - 2761   2020

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japanese Society of Internal Medicine  

    Breast involvement of Adult T-cell leukemia-lymphoma (ATLL) is extremely rare, and the data on the characteristics are limited. We herein describe a 49-year-old woman who presented with skin involvement of ATLL. Positron emission tomography/computed tomography showed bilateral breast lesions. Although the patient once achieved a complete metabolic response, a relapse of her ATLL occurred. The patient received subsequent allogeneic hematopoietic stem cell transplantation (HSCT). To our knowledge, only four cases of ATLL with breast involvement have previously been reported, and the prognoses have generally been poor. Breast lesions of ATLL have aggressive features, and intensive systemic chemotherapy and HSCT are required to improve survival.

    DOI: 10.2169/internalmedicine.5077-20

    PubMed

    researchmap

  • Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche Reviewed

    Maria Maryanovich, Ali H. Zahalka, Halley Pierce, Sandra Pinho, Fumio Nakahara, Noboru Asada, Qiaozhi Wei, Xizhe Wang, Paul Ciero, Jianing Xu, Avigdor Leftin, Paul S. Frenette

    Nature Medicine   24 ( 6 )   782 - 791   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Nature Publishing Group  

    Aging of hematopoietic stem cells (HSCs) is associated with a decline in their regenerative capacity and multilineage differentiation potential, contributing to the development of blood disorders. The bone marrow microenvironment has recently been suggested to influence HSC aging, but the underlying mechanisms remain largely unknown. Here we show that HSC aging critically depends on bone marrow innervation by the sympathetic nervous system (SNS), as loss of SNS nerves or adrenoreceptor β3 signaling in the bone marrow microenvironment of young mice led to premature HSC aging, as evidenced by appearance of HSC phenotypes reminiscent of physiological aging. Strikingly, supplementation of a sympathomimetic acting selectively on adrenoreceptor β3 to old mice significantly rejuvenated the in vivo function of aged HSCs, suggesting that the preservation or restitution of bone marrow SNS innervation during aging may hold the potential for new HSC rejuvenation strategies.

    DOI: 10.1038/s41591-018-0030-x

    Scopus

    PubMed

    researchmap

  • Regulation of malignant hematopoiesis by bone marrow microenvironment Reviewed

    Noboru Asada

    Frontiers in Oncology   8   119   2018.4

     More details

    Authorship:Corresponding author   Language:English   Publisher:Frontiers Media S.A.  

    Hematopoietic stem cells (HSCs) that give rise to all kinds of hematopoietic lineage cells on various demands throughout life are maintained in a specialized microenvironment called "niche" in the bone marrow (BM). Defining niche cells and unveiling its function have been the subject of intense study, and it is becoming increasingly clear how niche cells regulate HSCs in normal hematopoiesis. Leukemia stem cells (LSCs), which are able to produce leukemic cells and maintain leukemic clones, are assumed to share common features with healthy HSCs. Accumulating evidence suggests that LSCs reside in a specialized BM microenvironment
    moreover, LSCs could control and rebuild the microenvironment to enhance their progression and survival. This article discusses the recent advances in our knowledge of the microenvironment supporting malignant hematopoiesis, including LSC niche.

    DOI: 10.3389/fonc.2018.00119

    Scopus

    PubMed

    researchmap

  • The hematopoietic stem cell niche: from embryo to adult. Reviewed

    Gao X, Xu C, Asada N, Frenette PS

    Development (Cambridge, England)   145 ( 2 )   2018.1

  • A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche. Reviewed

    Guarnerio J, Mendez LM, Asada N, Menon AV, Fung J, Berry K, Frenette PS, Ito K, Pandolfi PP

    Nature communications   9 ( 1 )   66   2018.1

  • Complexity of bone marrow hematopoietic stem cell niche Reviewed

    Noboru Asada, Shoichiro Takeishi, Paul S. Frenette

    INTERNATIONAL JOURNAL OF HEMATOLOGY   106 ( 1 )   45 - 54   2017.7

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER JAPAN KK  

    Hematopoietic stem cells (HSCs) that produce a variety of hematopoietic lineage cells throughout the life reside in specialized microenvironment called "niche" in the bone marrow (BM) where they are tightly regulated. With the recent advances in experimental technologies enabling the selective deletion of molecules, various types of cells in the BM have been proposed to contribute to HSC niche activity. Among these are stromal cells closely associated with the vasculature. In this review, we provide an overview of recent advances in HSC niche research, and focus on the studies describing the functional roles of perivascular cells for HSC maintenance and mobilization. Not only for physiologic state, we also discuss the recent evidences suggesting the importance of microenvironment for emergence of malignant hematopoietic diseases.

    DOI: 10.1007/s12185-017-2262-9

    Web of Science

    PubMed

    researchmap

  • Differential cytokine contributions of perivascular haematopoietic stern cell niches Reviewed

    Noboru Asada, Yuya Kunisaki, Halley Pierce, Zichen Wang, Nicolas F. Fernandez, Alexander Birbrair, Avi Ma'ayan, Paul S. Frenette

    NATURE CELL BIOLOGY   19 ( 3 )   214 - 223   2017.3

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    Arterioles and sinusoids of the bone marrow (BM) are accompanied by stromal cells that express nerve/glial antigen 2 (NG2) and leptin receptor (LepR), and constitute specialized niches that regulate quiescence and proliferation of haematopoietic stem cells (HSCs). However, how niche cells differentially regulate HSC functions remains unknown. Here, we show that the effects of cytokines regulating HSC functions are dependent on the producing cell sources. Deletion of chemokine C-X-C motif ligand 12 (Cxcl12) or stem cell factor (Scf) from all perivascular cells marked by nestin-GFP dramatically depleted BM HSCs. Selective Cxcl12 deletion from arteriolar NG2(+) cells, but not from sinusoidal LepR(+) cells, caused HSC reductions and altered HSC localization in BM. By contrast, deletion of Scf in LepR(+) cells, but not NG2(+) cells, led to reductions in BM HSC numbers. These results uncover distinct contributions of cytokines derived from perivascular cells in separate vascular niches to HSC maintenance.

    DOI: 10.1038/ncb3475

    Web of Science

    PubMed

    researchmap

  • G-CSF-induced sympathetic tone provokes fever and primes antimobilizing functions of neutrophils via PGE(2) Reviewed

    Yuko Kawano, Chie Fukui, Masakazu Shinohara, Kanako Wakahashi, Shinichi Ishii, Tomohide Suzuki, Mari Sato, Noboru Asada, Hiroki Kawano, Kentaro Minagawa, Akiko Sada, Tomoyuki Furuyashiki, Satoshi Uematsu, Shizuo Akira, Toshimitsu Uede, Shuh Narumiya, Toshimitsu Matsui, Yoshio Katayama

    BLOOD   129 ( 5 )   587 - 597   2017.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC HEMATOLOGY  

    Granulocyte colony-stimulating factor (G-CSF) is widely used for peripheral blood stem/ progenitor mobilization. G-CSF causes low-grade fever that is ameliorated by nonsteroidal anti-inflammatory drugs (NSAIDs), suggesting the activation of arachidonic acid (AA) cascade. How G-CSF regulated this reaction was assessed. G-CSF treatment in mice resulted in fever, which was canceled in prostaglandin E synthase (mPGES-1)-deficient mice. Mobilization efficiency was twice as high in chimeric mice lacking mPGES-1, specifically in hematopoietic cells, suggesting that prostaglandin E-2 (PGE(2)) from hematopoietic cells modulated the bone marrow (BM) microenvironment. Neutrophils from steady-state BM constitutively expressed mPGES-1 and significantly enhanced PGE(2) production in vitro by beta-adrenergic stimulation, but not by G-CSF, which was inhibited by an NSAID. Although neutrophils expressed all beta-adrenergic receptors, only beta-agonist induced this phenomenon. Liquid chromatography-tandem mass spectrometry traced b-agonist-induced PGE(2) synthesis from exogenous deuterium-labeled AA. Spontaneous PGE(2) production was highly efficient in Gr-1(high) neutrophils among BM cells from G-CSF-treated mice. In addition to these in vitro data, the in vivo depletion of Gr-1(high) neutrophils disrupted G-CSF-induced fever. Furthermore, sympathetic denervation eliminated both neutrophil priming for PGE(2) production and fever during G-CSF treatment. Thus, sympathetic tone-primed BM neutrophils were identified as one of the major PGE(2) producers. PGE(2) upregulated osteopontin, specifically in preosteoblasts, to retain progenitors in the BM via EP4 receptor. Thus, the sympathetic nervous system regulated neutrophils as an indispensable PGE(2) source to modulateBM microenvironment and body temperature. This study provided a novel mechanistic insight into the communication of the nervous system, BMniche components, and hematopoietic cells.

    DOI: 10.1182/blood-2016-07-725754

    Web of Science

    PubMed

    researchmap

  • Communication of bone cells with hematopoiesis, immunity and energy metabolism. Reviewed International journal

    Asada N, Sato M, Katayama Y

    BoneKEy reports   4   748 - 748   2015

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    The bone contains the bone marrow. The functional communication between bone cells and hematopoiesis has been extensively studied in the past decade or so. Osteolineage cells and their modulators, such as the sympathetic nervous system, macrophages and osteoclasts, form a complex unit to maintain the homeostasis of hematopoiesis, called the 'microenvironment'. Recently, bone-embedded osteocytes, the sensors of gravity and mechanical stress, have joined the microenvironment, and they are demonstrated to contribute to whole body homeostasis through the control of immunity and energy metabolism. The inter-organ communication orchestrated by the bone is summarized in this article.

    DOI: 10.1038/bonekey.2015.117

    PubMed

    researchmap

  • Regulation of hematopoiesis in endosteal microenvironments Reviewed

    Noboru Asada, Yoshio Katayama

    INTERNATIONAL JOURNAL OF HEMATOLOGY   99 ( 6 )   679 - 684   2014.6

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER JAPAN KK  

    After birth, the hematopoietic system develops along with bone formation in mammals. Osteolineage cells are derived from mesenchymal progenitor cells, and differentiate into several types of bone-forming cells. Of the various types of cell constituents in bone marrow, osteolineage cells have been shown to play important roles in hematopoiesis. Early studies have identified osteoblasts as a hematopoietic stem cell niche component. Since that time, the role of endosteal microenvironment as a critical regulator of hematopoietic stem/progenitor cell (HSC/HPC) behavior has been appreciated particularly under stress conditions, such as cytokine-induced HSC/HPC mobilization, homing/engraftment after bone marrow transplantation, and disease models of leukemia/myelodysplasia. Recent studies revealed that the most differentiated osteolineage cells, i.e., osteocytes, play important roles in the regulation of hematopoiesis. In this review, we provide an overview of recent advances in knowledge of regulatory hematopoietic mechanisms in the endosteal area.

    DOI: 10.1007/s12185-014-1583-1

    Web of Science

    PubMed

    researchmap

  • Osteocytes Regulate Primary Lymphoid Organs and Fat Metabolism Reviewed

    Mari Sato, Noboru Asada, Yuko Kawano, Kanako Wakahashi, Kentaro Minagawa, Hiroki Kawano, Akiko Sada, Kyoji Ikeda, Toshimitsu Matsui, Yoshio Katayama

    CELL METABOLISM   18 ( 5 )   749 - 758   2013.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:CELL PRESS  

    Osteocytes act as mechanosensors to control local bone volume. However, their roles in the homeostasis of remote organs are largely unknown. We show that ablation of osteocytes in mice (osteocyte-less [OL] mice) leads to severe lymphopenia, due to lack of lymphoid-supporting stroma in both the bone marrow and thymus, and complete loss of white adipose tissues. These effects were reversed when osteocytes were replenished within the bone. In contrast, neither in vivo supply of T cell progenitors and humoral factors via shared circulation with a normal parabiotic partner nor ablation of specific hypothalamic nuclei rescued thymic atrophy and fat loss in OL mice. Furthermore, ablation of the hypothalamus in OL mice led to hepatic steatosis, which was rescued by parabiosis with normal mice. Our results define a role for osteocytes as critical regulators of lymphopoiesis and fat metabolism and suggest that bone acts as a central regulator of multiple organs.

    DOI: 10.1016/j.cmet.2013.09.014

    Web of Science

    PubMed

    researchmap

  • Matrix-Embedded Osteocytes Regulate Mobilization of Hematopoietic Stem/Progenitor Cells Reviewed

    Noboru Asada, Yoshio Katayama, Mari Sato, Kentaro Minagawa, Kanako Wakahashi, Hiroki Kawano, Yuko Kawano, Akiko Sada, Kyoji Ikeda, Toshimitsu Matsui, Mitsune Tanimoto

    CELL STEM CELL   12 ( 6 )   737 - 747   2013.6

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:CELL PRESS  

    The bone marrow (BM) niche comprises multiple cell types that regulate hematopoietic stem/progenitor cell (HSPC) migration out of the niche and into the circulation. Here, we demonstrate that osteocytes, the major cellular component of mature bone, are regulators of HSPC egress. Granulocyte colony-stimulating factor (G-CSF), used clinically to mobilize HSPCs, induces changes in the morphology and gene expression of the osteocytic network that precedes changes in osteoblasts. This rapid response is likely under control of the sympathetic nervous system, since osteocytes express the b2-adrenergic receptor and surgical sympathectomy prevents it. Mice with targeted ablation of osteocytes or a disrupted osteocyte network have comparable numbers of HSPCs in the BM but fail to mobilize HSPCs in response to G-CSF. Taken together, these results indicate that the BM/bone niche interface is critically controlled from inside of the bone matrix and establish an important physiological role for skeletal tissues in hematopoietic function.

    DOI: 10.1016/j.stem.2013.05.001

    Web of Science

    PubMed

    researchmap

  • Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma Reviewed

    Kosei Matsue, Noboru Asada, Jun Odawara, Takayoshi Aoki, Shun-ichi Kimura, Kan-ichi Iwama, Hideaki Fujiwara, Masayuki Yamakura, Masami Takeuchi

    ANNALS OF HEMATOLOGY   90 ( 4 )   417 - 421   2011.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER  

    Intravascular lymphoma (IVL) is a rare type of extranodal lymphoma in which the lymphoma cells proliferate exclusively in the lumina of small vessels. The diagnosis of IVL requires histological confirmation. Although random skin biopsy from healthy-appearing skin in patients with suspected IVL appeared to be useful, the sensitivity of this method for the diagnosis of IVL remains unknown. We performed a random skin biopsy from 12 consecutive cases of IVL diagnosed at our institution over the past 4 years and evaluate its relevance of clinical and laboratory characteristics, presence or absence of skin lesions, and bone marrow involvement. All 12 patients were diagnosed antemortem by either random skin biopsy or bone marrow biopsy and treated with rituximab-containing chemotherapy. Random skin biopsy was performed in all 12 patients, and the results were positive in ten patients (83.3%). Erythematous skin lesions were seen in 3 of 12 patients, but biopsy was positive for lymphoma lesion in two patients. Bone marrow invasion was seen in 11 of the 12 patients (91.6%) by bone marrow smear and/or flow cytometric analysis, but was detected in only half of the patients by trephine biopsy. We concluded that random skin biopsy from normal-appearing skin is highly sensitive in the diagnosis of IVL comparable to bone marrow trephine biopsy. It should be performed irrespective of the presence or absence of skin lesions in patients who were suspicious of IVL.

    DOI: 10.1007/s00277-010-1101-3

    Web of Science

    PubMed

    researchmap

  • Role for vitamin D receptor in the neuronal control of the hematopoietic stem cell niche Reviewed

    Yuriko Kawamori, Yoshio Katayama, Noboru Asada, Kentaro Minagawa, Mari Sato, Atsuo Okamura, Manabu Shimoyama, Kimie Nakagawa, Toshio Okano, Mitsune Tanimoto, Shigeaki Kato, Toshimitsu Matsui

    BLOOD   116 ( 25 )   5528 - 5535   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC HEMATOLOGY  

    Hematopoietic stem/progenitor cells (HSPCs) are released from the bone marrow to the circulation by the cytokine, granulocyte colony-stimulating factor, via sympathetic nervous system (SNS)-mediated osteoblast suppression. Because the orientation of HSPCs in their osteoblastic niche is reported to be guided by [Ca(2+)], we speculated on a cooperation between the calcium-regulating hormones and SNS in the regulation of HSPC trafficking. Here, we present the severe impairment of granulocyte colony-stimulating factor-induced osteoblast suppression and subsequent HSPC mobilization in vitamin D receptor (VDR)-deficient mice. In osteoblasts, functional VDR possessing, at least in part, a transcriptional activity, was specifically induced by beta 2-adrenergic receptor (AR) agonists. While beta 2-AR agonists transiently increased mRNA expression of Vdr and its downstream gene, Rankl, 1 alpha,25-dihydroxyvitamin-D(3) sustained the beta 2-AR-induced Rankl expression at high level by stabilizing VDR protein. These data suggest that VDR is essential for durable beta 2-AR signaling in the stem cell niche. Our study demonstrates not only a novel function of VDR as a critical modulator of HSPC trafficking, but also the presence of a SNS-mediated, bone-remodeling mechanism through VDR. VDR contributes to brain-bone-blood integration in an unanticipated way distinct from other classical calcium-regulating hormones. (Blood. 2010; 116(25): 5528-5535)

    DOI: 10.1182/blood-2010-04-279216

    Web of Science

    PubMed

    researchmap

  • Progressive osteosclerosis and visceral calcification after cord blood transplantation Reviewed

    Noboru Asada, Shinichi Ishii, Kanako Wakahashi, Hiroki Kawano, Yuriko Kawamori, Shinichiro Nishikawa, Kentaro Minagawa, Atsuo Okamura, Manabu Shimoyama, Yoshio Katayama, Yoshitake Hayashi, Tomoo Itoh, Mitsune Tanimoto, Toshimitsu Matsui

    INTERNATIONAL JOURNAL OF HEMATOLOGY   91 ( 3 )   542 - 545   2010.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER TOKYO  

    A 26-year-old woman, who successfully underwent umbilical cord blood transplantation for aplastic anemia 4 years previously, had suffered from hepatosplenic microabscesses caused by unidentifiable grocott stain-positive spores from immediately after the transplantation. At 51 months post-transplant, we attempted bone marrow biopsy from her posterior iliac crest, but failed to penetrate the cortical bone. X-ray of her spine and pelvis showed marked and diffuse osteosclerosis. Retrospective analysis of computed tomography revealed the gradual replacement of sternal, vertebral, and pelvic bone marrow with calcified tissues in addition to the dispersed calcification of the liver, spleen, and kidneys over the last 2 years. The bone mineral density of the lumbar spine had increased but not that of the femoral neck. Biomedical parameters for bone remodeling demonstrated enhanced bone formation as well as bone resorption and secondary hyperparathyroidism. Based on the past reports, we suggest that chronic fungal infection, which caused visceral calcification, induced the production of humoral factors for osteoblastic activation.

    DOI: 10.1007/s12185-010-0524-x

    Web of Science

    PubMed

    researchmap

  • Use of random skin biopsy for diagnosis of intravascular large B-Cell lymphoma Reviewed

    Noboru Asada, Jun Odawara, Shun-Ichi Kimura, Takatoshi Aoki, Masayuki Yamakura, Masami Takeuchi, Reiko Seki, Atsushi Tanaka, Kosei Matsue

    MAYO CLINIC PROCEEDINGS   82 ( 12 )   1525 - 1527   2007.12

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER SCIENCE INC  

    Intravascular lymphoma (IVL) is a rare type of extranodal lymphoma with an aggressive clinical course characterized by proliferation of large lymphoma cells within the lumina of the small vessels. Because of its varied clinical symptoms and the absence of lymphadenopathy, diagnosis of IVL is extremely difficult and requires histological confirmation. We report here 6 consecutive patients with IVL, admitted to Kameda General Hospital, Kamogawa-shi, Japan, from June 7, 2006, to February 28, 2007, whose IVL was diagnosed by random skin biopsy of healthy-appearing skin. Three patients presented with progressive neurological deterioration and 2 others with hypoxemia with interstitial infiltration on chest radiography. One patient presented with confusion and severe hypoxia without apparent interstitial Infiltration. Two patients showed localized skin involvement. Irrespective of the presence of skin lesions, almost all skin biopsy specimens showed obliteration of small vessels of subcutaneous fat tissues by lymphoma cells, allowing a prompt diagnosis of IVL. Early institution of rituximab-based chemotherapy induced favorable responses in all patients treated. Because diagnosis based on tissue other than skin is usually difficult In patients with suspected IVL, random skin biopsy should be considered even in patients with no evident skin lesions.

    DOI: 10.4065/82.12.1525

    Web of Science

    PubMed

    researchmap

  • 血液疾患患者におけるミカファンギン投与による侵襲性トリコスポロン症のbreakthrough感染症の検討

    淺田騰, 瓜生英尚, 小関美保子, 竹内正美, 福田隆浩, 杉山暖子, 前田嘉信, 山筋好子, 進藤基博, 今村豊, 末永孝生

    臨床血液   47 ( 9 )   1144   2006.9

     More details

    Authorship:Lead author   Language:Japanese  

    J-GLOBAL

    researchmap

  • Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia Reviewed

    Noboru Asada, Hidetaka Uryu, Mihoko Koseki, Masami Takeuchi, Masaru Komatsu, Kosei Matsue

    CLINICAL INFECTIOUS DISEASES   43 ( 4 )   E39 - E41   2006.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:UNIV CHICAGO PRESS  

    We describe a 55-year-old man with acute myelogenous leukemia who developed breakthrough Trichosporon asahii fungemia during 5 days of micafungin treatment. Although the patient's clinical condition improved considerably after the start of voriconazole treatment, blood culture results remained positive for T. asahii for 3 days, and fever persisted for 7 days thereafter. The patient achieved complete hematological remission, and he received successful consolidation chemotherapy without developing Trichosporon infection with the prophylactic use of voriconazole therapy. This case report illustrates that voriconazole may be useful in the treatment of disseminated T. asahii infection in neutropenic patients.

    DOI: 10.1086/505970

    Web of Science

    PubMed

    researchmap

  • Antitumor activity of α-pinene in T-cell tumors. International journal

    Masaya Abe, Noboru Asada, Maiko Kimura, Chie Fukui, Daisuke Yamada, Ziyi Wang, Masayuki Miyake, Takeshi Takarada, Mitsuaki Ono, Michinori Aoe, Wataru Kitamura, Masayuki Matsuda, Takashi Moriyama, Akifumi Matsumura, Yoshinobu Maeda

    Cancer science   2024.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    T-cell acute leukemia and lymphoma have a poor prognosis. Although new therapeutic agents have been developed, their therapeutic effects are suboptimal. α-Pinene, a monoterpene compound, has an antitumor effect on solid tumors; however, few comprehensive investigations have been conducted on its impact on hematologic malignancies. This report provides a comprehensive analysis of the potential benefits of using α-pinene as an antitumor agent for the treatment of T-cell tumors. We found that α-pinene inhibited the proliferation of hematologic malignancies, especially in T-cell tumor cell lines EL-4 and Molt-4, induced mitochondrial dysfunction and reactive oxygen species accumulation, and inhibited NF-κB p65 translocation into the nucleus, leading to robust apoptosis in EL-4 cells. Collectively, these findings suggest that α-pinene has potential as a therapeutic agent for T-cell malignancies, and further investigation is warranted.

    DOI: 10.1111/cas.16086

    PubMed

    researchmap

  • CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. Reviewed International journal

    Naofumi Hara, Eiki Ichihara, Hirohisa Kano, Chihiro Ando, Ayako Morita, Tatsuya Nishi, Sachi Okawa, Takamasa Nakasuka, Atsuko Hirabae, Masaya Abe, Noboru Asada, Kiichiro Ninomiya, Go Makimoto, Masanori Fujii, Toshio Kubo, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

    Translational lung cancer research   12 ( 10 )   2098 - 2112   2023.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletion and exon 21 L858R, are driver oncogenes of non-small cell lung cancer (NSCLC), with EGFR tyrosine kinase inhibitors (TKIs) being effective against EGFR-mutant NSCLC. However, the efficacy of EGFR-TKIs is transient and eventually leads to acquired resistance. Herein, we focused on the significance of cell cycle factors as a mechanism to attenuate the effect of EGFR-TKIs in EGFR-mutant NSCLC before the emergence of acquired resistance. METHODS: Using several EGFR-mutant cell lines, we investigated the significance of cell cycle factors to attenuate the effect of EGFR-TKIs in EGFR-mutant NSCLC. RESULTS: In several EGFR-mutant cell lines, certain cancer cells continued to proliferate without EGFR signaling, and the cell cycle regulator retinoblastoma protein (RB) was not completely dephosphorylated. Further inhibition of phosphorylated RB with cyclin-dependent kinase (CDK) 4/6 inhibitors, combined with the EGFR-TKI osimertinib, enhanced G0/G1 cell cycle accumulation and growth inhibition of the EGFR-mutant NSCLC in both in vitro and in vivo models. Furthermore, residual RB phosphorylation without EGFR signaling was maintained by extracellular signal-regulated kinase (ERK) signaling, and the ERK inhibition pathway showed further RB dephosphorylation. CONCLUSIONS: Our study demonstrated that the CDK4/6-RB signal axis, maintained by the MAPK pathway, attenuates the efficacy of EGFR-TKIs in EGFR-mutant NSCLC, and targeting CDK4/6 enhances this efficacy. Thus, combining CDK4/6 inhibitors and EGFR-TKI could be a novel treatment strategy for TKI-naïve EGFR-mutant NSCLC.

    DOI: 10.21037/tlcr-23-99

    PubMed

    researchmap

  • Evaluating the efficiency and safety of large-volume leukapheresis using the Spectra Optia continuous mononuclear cell collection protocol for peripheral blood stem cell collection from healthy donors: A retrospective study. Reviewed International journal

    Yuichi Sumii, Keiko Fujii, Takumi Kondo, Tomohiro Urata, Maiko Kimura, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda, Nobuharu Fujii

    Transfusion   2023.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Large-volume leukapheresis (LVL) refers to processing of more than three volumes of blood in a single session for peripheral blood stem cell collection. Recently, continuous mononuclear cell collection (cMNC) protocol has been developed using the Spectra Optia system, which is a widely used apheresis device. LVL using the novel protocol has been investigated in patients. However, the efficiency and safety of LVL in healthy donors using this protocol has not been characterized. Therefore, this study aimed to evaluate the efficiency and tolerability of CD34+ collection of LVL with the cMNC protocol in healthy donors. STUDY DESIGN AND METHODS: We retrospectively collected data on LVL (>3 total blood volume) and normal-volume leukapheresis (NVL) performed in healthy donors between October 2019 and December 2021. All procedures were performed using the cMNC protocol. RESULTS: Although pre-apheresis CD34+ cell count was lesser in LVL (23.5 vs. 58.0/μL, p < .001), CD34+ collection efficiency was comparable between LVL and NVL (61.2% vs. 61.4%, p = .966). Platelet loss was significantly higher in LVL compared to NVL (38.0% vs. 29.4%, p < .001), with no correlation between attrition of platelet and processing blood volume. Moreover, the incidence of citrate toxicity during procedures was comparable between the two groups (31.6% vs. 21.4%, p = .322). All LVL procedures could be completed without any adverse events. CONCLUSION: Allogeneic LVL procedure using Spectra Optia cMNC protocol was well tolerated by the donors and resulted in efficient collection of CD34+ cells, which was comparable to that of NVL.

    DOI: 10.1111/trf.17563

    PubMed

    researchmap

  • 再発・難治性びまん性大細胞型B細胞性リンパ腫に対するtisagenlecleucel輸注後の早期再燃を予測する輸注前因子の検討

    北村 亘, 藤井 伸治, 鴨井 千尋, 浦田 知宏, 小林 宏紀, 山本 晃, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本造血・免疫細胞療法学会雑誌   12 ( 4 )   259 - 267   2023.10

     More details

    Language:Japanese   Publisher:(一社)日本造血・免疫細胞療法学会  

    researchmap

  • Distribution and clinical impact of molecular subtypes with Dark Zone signature of DLBCL in a Japanese real-world study. Reviewed International journal

    Tomohiro Urata, Yusuke Naoi, Aixiang Jiang, Merrill Boyle, Kazutaka Sunami, Toshi Imai, Yuichiro Nawa, Yasushi Hiramatsu, Kazuhiko Yamamoto, Soichiro Fujii, Isao Yoshida, Tomofumi Yano, Ryota Chijimatsu, Hiroyuki Murakami, Kazuhiro Ikeuchi, Hiroki Kobayashi, Katsuma Tani, Hideki Ujiie, Hirofumi Inoue, Shuta Tomida, Akira Yamamoto, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Keisuke Sawada, Shuji Momose, Jun-Ichi Tamaru, Asami Nishikori, Yasuharu Sato, Tadashi Yoshino, Yoshinobu Maeda, David W Scott, Daisuke Ennishi

    Blood advances   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The distribution and clinical impact of cell-of-origin (COO) subtypes of diffuse large B-cell lymphoma (DLBCL) outside Western countries remain unknown. Recent literature also suggests that there is an additional COO subtype associated with the germinal center dark zone, that warrants wider validation to generalize clinical relevance. Here, we assembled a cohort of Japanese patients with untreated DLBCL and determined the refined COO subtypes, that include the dark zone signature (DZsig), using the NanoString DLBCL90 assay. To compare the distribution and clinical characteristics of the molecular subtypes, we used a dataset from the cohort of BC Cancer (BCC) (n = 804). Of the 1050 patients where DLBCL90 assay was successfully performed in our cohort, 35%, 45%, and 6% of patients were identified to be germinal center B-cell-like (GCB)-DLBCL, activated B-cell-like (ABC)-DLBCL, and DZsigpos-DLBCL, respectively, with the highest prevalence of ABC-DLBCL differing significantly from that of BCC (P < 0.001). GCB-DLBCL, ABC-DLBCL, and DZsigpos-DLBCL were associated with two-year overall survival rates of 88%, 75%, and 66%, respectively (P < 0.0001), with patients of the DZsigpos-DLBCL having the poorest prognosis. In contrast, GCB-DLBCL without DZsig showed excellent outcomes following rituximab-containing immunochemotherapy. DZsigpos-DLBCL was associated with the significant enrichment of tumors with CD10 expression, concurrent MYC/BCL2 expression, and depletion of microenvironmental components (all P < 0.05). These results provide evidence of the distinct distribution of clinically relevant molecular subtypes in Japanese DLBCL and that refined COO, as measured by the DLBCL90 assay, is a robust prognostic biomarker that is consistent across geographical areas.

    DOI: 10.1182/bloodadvances.2023010402

    PubMed

    researchmap

  • Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel. Reviewed International journal

    Toshiki Terao, Wataru Kitamura, Nobuharu Fujii, Noboru Asada, Chihiro Kamoi, Kanako Fujiwara, Kaho Kondo, Chisato Matsubara, Kenta Hayashino, Keisuke Seike, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Transplantation and cellular therapy   29 ( 9 )   573.e1-573.e8   2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The prognostic impact of corticosteroid therapy in patients receiving tisagenlecleucel (tisa-cel) treatment who are more likely to develop cytokine release syndrome (CRS) remains unclear. This study aimed to evaluate the clinical impact and lymphocyte kinetics of corticosteroid administration for CRS in 45 patients with relapsed and/or refractory B-cell lymphoma treated with tisa-cel. This was a retrospective evaluation of all consecutive patients diagnosed with relapsed and/or refractory diffuse large B-cell lymphoma, follicular lymphoma with histologic transformation to large B-cell lymphoma, or follicular lymphoma who received commercial-based tisa-cel treatment. The best overall response rate, complete response rate, median progression-free survival (PFS), and median overall survival (OS) were 72.7%, 45.5%, 6.6 months, and 15.3 months, respectively. CRS (predominantly grade 1/2) occurred in 40 patients (88.9%), and immune effector cell-associated neurotoxicity syndrome (ICANS) of all grades occurred in 3 patients (6.7%). No grade ≥3 ICANS occurred. Patients with high-dose (≥524 mg, methylprednisolone equivalent; n = 12) or long-term (≥8 days; n = 9) corticosteroid use had inferior PFS and OS to patients with low-dose or no corticosteroid use (both P < .05). The prognostic impact remained even in 23 patients with stable disease (SD) or progressive disease (PD) before tisa-cel infusion (P = .015). but not in patients with better disease status (P = .71). The timing of corticosteroid initiation did not have a prognostic impact. Multivariate analysis identified high-dose corticosteroid use and long-term corticosteroid use as independent prognostic factors for PFS and OS, respectively, after adjusting for elevated lactate dehydrogenase level before lymphodepletion chemotherapy and disease status (SD or PD). Lymphocyte kinetics analysis demonstrated that after methylprednisolone administration, the proportions of regulatory T cells (Tregs), CD4+ central memory T (TCM) cells, and natural killer (NK) cells were decreased, whereas the proportion of CD4+ effector memory T (TEM) cells was increased. Patients with a higher proportion of Tregs at day 7 had a lower incidence of CRS, but this did not affect prognosis, indicating that early elevation of Tregs may serve as a biomarker for CRS development. Furthermore, patients with higher numbers of CD4+ TCM cells and NK cells at various time points had significantly better PFS and OS, whereas the number of CD4+ TEM cells did not impact prognostic outcomes. This study suggests that high-dose or long-term corticosteroid use attenuates the efficacy of tisa-cel, especially in patients with SD or PD. Additionally, patients with high levels of CD4+ TCM cells and NK cells after tisa-cel infusion had longer PFS and OS.

    DOI: 10.1016/j.jtct.2023.06.018

    PubMed

    researchmap

  • Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch Reviewed

    Takumi Kondo, Keiko Fujii, Nobuharu Fujii, Yuichi Sumii, Tomohiro Urata, Maiko Kimura, Masayuki Matsuda, Shuntaro Ikegawa, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   2023.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    DOI: 10.1111/trf.17450

    researchmap

  • Hematopoietic stem cell–derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide Reviewed

    Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Takuya Fukumi, Miki Iwamoto, Midori Filiz Nishimura, Hiroyuki Sugiura, Yasuhisa Sando, Makoto Nakamura, Yusuke Meguri, Takashi Matsushita, Naoki Tanimine, Maiko Kimura, Noboru Asada, Daisuke Ennishi, Yoshinobu Maeda, Ken-ichi Matsuoka

    JCI Insight   8 ( 8 )   2023.4

     More details

    Publishing type:Research paper (scientific journal)   Publisher:American Society for Clinical Investigation  

    DOI: 10.1172/jci.insight.162180

    researchmap

  • Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan. Reviewed International journal

    Noboru Asada, Jun Ando, Satoru Takada, Chikashi Yoshida, Kensuke Usuki, Atsushi Shinagawa, Kenichi Ishizawa, Toshihiro Miyamoto, Hiroatsu Iida, Nobuaki Dobashi, Sumiko Okubo, Hideyuki Honda, Tomomi Soshin, Yasuko Nishimura, Atsuko Tsutsui, Harumi Mukai, Kazuhito Yamamoto

    Japanese journal of clinical oncology   2023.4

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: In a Phase 3 international clinical trial (VIALE-C), venetoclax plus low-dose cytarabine improved the response rate and overall survival versus placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy. After the enrollment period of VIALE-C ended, we conducted an expanded access study to provide preapproval access to venetoclax in combination with low-dose cytarabine in Japan. METHODS: Previously, untreated patients with acute myeloid leukemia who were ineligible for intensive chemotherapy were enrolled according to the VIALE-C criteria. Patients received venetoclax (600 mg, Days 1-28, 4-day ramp-up in Cycle 1) in 28-day cycles and low-dose cytarabine (20 mg/m2, Days 1-10). All patients took tumor lysis syndrome prophylactic agents and hydration. Safety endpoints were assessed. RESULTS: Fourteen patients were enrolled in this study. The median age was 77.5 years (range = 61-84), with 78.6% over 75 years old. The most common grade ≥ 3 treatment-emergent adverse event was neutropenia (57.1%). Febrile neutropenia was the most frequent serious adverse event (21.4%). One patient developed treatment-related acute kidney injury, leading to discontinuation of treatment. Two patients died because of cardiac failure and disease progression that were judged not related to study treatment. No patients developed tumor lysis syndrome. CONCLUSIONS: The safety outcomes were similar to those in VIALE-C without new safety signals and were well managed with standard medical care. In clinical practice, more patients with severe background disease are expected, in comparison with in VIALE-C, suggesting that it is important to carefully manage and prevent adverse events.

    DOI: 10.1093/jjco/hyad027

    PubMed

    researchmap

  • 当院における再発難治性びまん性大細胞型B細胞性リンパ腫に対するtisagenlecleucelの治療成績

    北村 亘, 藤井 伸治, 鴨井 千尋, 阿部 将也, 住居 優一, 浦田 知宏, 谷 勝真, 高木 尚江, 山本 晃, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本輸血細胞治療学会誌   69 ( 2 )   331 - 331   2023.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    J-GLOBAL

    researchmap

  • 当院における再発難治性びまん性大細胞型B細胞性リンパ腫に対するtisagenlecleucelの治療成績

    北村 亘, 藤井 伸治, 鴨井 千尋, 阿部 将也, 住居 優一, 浦田 知宏, 谷 勝真, 高木 尚江, 山本 晃, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本輸血細胞治療学会誌   69 ( 2 )   331 - 331   2023.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • A mysterious triangle of blood, bones, and nerves. Reviewed

    Noboru Asada, Yoshio Katayama

    Journal of bone and mineral metabolism   2023.2

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    The relationship between bone tissue and bone marrow, which is responsible for hematopoiesis, is inseparable. Osteoblasts and osteocytes, which produce and consist of bone tissue, regulate the function of hematopoietic stem cells (HSC), the ancestors of all hematopoietic cells in the bone marrow. The peripheral nervous system finely regulates bone remodeling in bone tissue and modulates HSC function within the bone marrow, either directly or indirectly via modification of the HSC niche function. Peripheral nerve signals also play an important role in the development and progression of malignant tumors (including hematopoietic tumors) and normal tissues, and peripheral nerve control is emerging as a potential new therapeutic target. In this review, we summarize recent findings on the linkage among blood system, bone tissue, and peripheral nerves.

    DOI: 10.1007/s00774-023-01402-5

    PubMed

    researchmap

  • Tfl deletion induces extraordinary Cxcl13 secretion and cachexia in VavP-Bcl2 transgenic mice. Reviewed International journal

    Kentaro Minagawa, Kanako Wakahashi, Chie Fukui, Yuko Kawano, Hiroki Kawano, Tomohide Suzuki, Shinichi Ishii, Akiko Sada, Shinichiro Nishikawa, Noboru Asada, Yoshio Katayama, Toshimitsu Matsui

    Frontiers in immunology   14   1197112 - 1197112   2023

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Loss of TFL, found in several types of lymphoma, induces excessive CXCL13 secretion through RNA dysregulation contributing to body weight loss and early death in lymphoma model mice. Follicular lymphoma (FL) is associated with overexpressed BCL-2 and other genetic aberrations, including 6q-. We identified a novel gene on 6q25, "Transformed follicular lymphoma (TFL)," from a transformed FL. TFL regulates several cytokines via mRNA degradation, which has been suggested to underlie resolving inflammation. Fluorescence in situ hybridization revealed a deletion of TFL occurred in 13.6% of various B-cell lymphoma samples. We developed VavP-bcl2 transgenic, TFL deficit mice (Bcl2-Tg/Tfl -/-) to seek how TFL affects disease progression in this lymphoma model. While Bcl2-Tg mice developed lymphadenopathy and died around 50 weeks, Bcl2-Tg/Tfl -/- mice lost body weight around 30 weeks and died about 20 weeks earlier than Bcl2-Tg mice. Furthermore, we found a unique B220-IgM+ cell population in the bone marrow of Bcl2-Tg mice. cDNA array in this population revealed that Cxcl13 mRNA in Bcl2-Tg/Tfl -/- mice expressed significantly higher than Bcl2-Tg mice. In addition, bone marrow extracellular fluid and serum showed an extremely high Cxcl13 concentration in Bcl2-Tg/Tfl -/- mice. Among bone marrow cells, the B220-IgM+ fraction was the main producer of Cxcl13 in culture. A reporter assay demonstrated TFL regulates CXCL-13 via induction of 3'UTR mRNA degradation in B lineage cells. These data suggest Tfl regulates Cxcl13 in B220-IgM+ cells in the bone marrow, and a very high concentration of serum Cxcl13 arising from these cells may contribute to early death in lymphoma-bearing mice. Since several reports have suggested the association of CXCL13 expression with lymphoma, these findings provide new insights into cytokine regulation via TFL in lymphoma.

    DOI: 10.3389/fimmu.2023.1197112

    PubMed

    researchmap

  • Pre-infusion factors predicting early failure after tisagenlecleucel for patients with relapsed/refractory diffuse large B-cell lymphoma: A single institute retrospective analysis

    Wataru Kitamura, Nobuharu Fujii, Chihiro Kamoi, Tomohiro Urata, Hiroki Kobayashi, Akira Yamamoto, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Ken-ichi Matsuoka, Yoshinobu Maeda

    Japanese Journal of Transplantation and Cellular Therapy   12 ( 4 )   259 - 267   2023

     More details

    Publishing type:Research paper (scientific journal)   Publisher:The Japan Society for Hematopoietic Stem Cell Transplantation  

    DOI: 10.7889/tct-23-014

    researchmap

  • Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML. Reviewed International journal

    Toshiki Terao, Ken-Ichi Matsuoka, Hiroko Ueda, Akifumi Matsumura, Chisato Matsubara, Kaho Kondo, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    Blood advances   7 ( 5 )   681 - 686   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1182/bloodadvances.2022008991

    PubMed

    researchmap

  • Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Reviewed

    Yui Kambara, Nobuharu Fujii, Yoshiaki Usui, Akira Yamamoto, Hisao Higo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    International journal of hematology   117 ( 4 )   578 - 589   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Non-infectious pulmonary complications (NIPCs) after allogeneic hematopoietic stem cell transplantation (HSCT) are associated with poor outcomes. It is important to maximize the effectiveness of primary treatment because secondary treatment has not been established. We analyzed data from 393 patients who underwent allogeneic HSCT during a 10-year period. Thirty-seven were diagnosed with NIPCs, which consisted of idiopathic pneumonia syndrome, bronchiolitis obliterans, and interstitial lung disease including cryptogenic organizing pneumonia. Among these, 18 died (Dead group) while 19 remained alive (Alive group) during the study period. The median time between NIPC diagnosis and first administration of ≥ 1 mg/kg/day corticosteroids (prednisolone dose equivalent) was significantly longer in the Dead group than the Alive group, at 9 days versus 4 days (p = 0.01). We further divided these cases into those who received prednisolone within seven days and after 8 days. We found that the ≤ 7 days group were more likely to survive after their NIPC diagnosis compared to the ≥ 8 days group (p = 0.06). Our analysis showed that early initiation of corticosteroid therapy is associated with long-term survival in NIPCs.

    DOI: 10.1007/s12185-022-03517-3

    PubMed

    researchmap

  • Neuropeptide Y Antagonizes Development of Pulmonary Fibrosis Through IL-1β Inhibition. Reviewed International journal

    Junko Itano, Akihiko Taniguchi, Satoru Senoo, Noboru Asada, Yuka Gion, Yuria Egusa, Lili Guo, Naohiro Oda, Kota Araki, Yasuharu Sato, Shinichi Toyooka, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara

    American journal of respiratory cell and molecular biology   67 ( 6 )   654 - 665   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Neuropeptide Y, a 36-amino acid residue polypeptide, distributed throughout the nervous system, acts on various immune cells in many organs, including the respiratory system. However, little is known about its role in the pathogenesis of pulmonary fibrosis. This study was performed to determine the effects of neuropeptide Y on pulmonary fibrosis. Neuropeptide Y-deficient and wild-type mice were intratracheally administered bleomycin. Inflammatory cells, cytokine levels, and morphological morphometry of the lungs were analyzed. Serum neuropeptide Y levels were also measured in idiopathic pulmonary fibrosis patients and healthy controls. Neuropeptide Y-deficient mice exhibited significantly enhanced pulmonary fibrosis and higher IL-1β levels in the lungs compared to wild-type mice. Exogenous neuropeptide Y treatment suppressed the development of bleomycin-induced lung fibrosis and decreased IL-1β levels in the lungs. Moreover, IL-1β neutralization in neuropeptide Y-deficient mice attenuated the fibrotic changes. Neuropeptide Y decreased IL-1β release, and Y1 receptor antagonists inhibited IL-1β release and induced epithelial mesenchymal transition in human alveolar epithelial cells. Patients with idiopathic pulmonary fibrosis had lower neuropeptide Y and greater IL-1β levels in the serums compared to healthy controls. Neuropeptide Y expression was mainly observed around bronchial epithelial cells in human idiopathic pulmonary fibrosis lungs. These data suggest that neuropeptide Y plays a protective role against pulmonary fibrosis by suppressing IL-1β release and manipulating the neuropeptide Y-Y1 receptor axis could be a potential therapeutic strategy for delaying disease progression.

    DOI: 10.1165/rcmb.2021-0542OC

    PubMed

    researchmap

  • Successful haematopoietic progenitor cell collection by plerixafor in combination with reduced dose granulocyte colony-stimulating factor for severe hypoxemia provoked by high-dose granulocyte colony-stimulating factor administration. Reviewed International journal

    Yui Kambara, Noboru Asada, Kaori Kondo, Yuichi Sumii, Yuki Fujiwara, Keisuke Seike, Yasuhisa Sando, Kyosuke Saeki, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Transfusion medicine (Oxford, England)   2022.9

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/tme.12916

    PubMed

    researchmap

  • 末梢神経系による造血調節と腫瘍制御 Invited Reviewed

    淺田 騰

    臨床血液   63 ( 9 )   991 - 998   2022.9

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    神経系は全身の臓器に隈なくいきわたり,われわれの意識しないところで生体の恒常性維持を行っている。自律神経と感覚神経から構成される末梢神経系は,造血を司る骨髄やその周囲にあり造血機能にも重要な働きを持つ骨組織にも分布する。最近の研究手法の進歩により末梢神経系が正常造血あるいはストレス下での造血,さらには造血の老化に重要な働きを持ち,細やかな調節を行っていることが明らかになってきている。また,正常組織だけでなく,造血器腫瘍を含む悪性腫瘍の発生・進展のプロセスにおいても末梢神経シグナルが重要な役割を果たし,末梢神経制御が新たな治療ターゲットとなる可能性も出てきている。(著者抄録)

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2022&ichushi_jid=J01540&link_issn=&doc_id=20221004200002&doc_link_id=10.11406%2Frinketsu.63.991&url=https%3A%2F%2Fdoi.org%2F10.11406%2Frinketsu.63.991&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_2.gif

  • Red blood cell depletion in small‐volume bone marrow processing using manipulation with third‐party red blood cells: A comparison of the performance of the <scp>COBE</scp> spectra and the spectra Optia systems Reviewed

    Yuichi Sumii, Nobuharu Fujii, Keiko Fujii, Takumi Kondo, Tomohiro Urata, Maiko Kimura, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   2022.8

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    DOI: 10.1111/trf.17039

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/trf.17039

  • Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging Reviewed

    Ruzhica Bogeska, Ana-Matea Mikecin, Paul Kaschutnig, Malak Fawaz, Marleen Büchler-Schäff, Duy Le, Miguel Ganuza, Angelika Vollmer, Stella V. Paffenholz, Noboru Asada, Esther Rodriguez-Correa, Felix Frauhammer, Florian Buettner, Melanie Ball, Julia Knoch, Sina Stäble, Dagmar Walter, Amelie Petri, Martha J. Carreño-Gonzalez, Vinona Wagner, Benedikt Brors, Simon Haas, Daniel B. Lipka, Marieke A.G. Essers, Vivienn Weru, Tim Holland-Letz, Jan-Philipp Mallm, Karsten Rippe, Stephan Krämer, Matthias Schlesner, Shannon McKinney Freeman, Maria Carolina Florian, Katherine Y. King, Paul S. Frenette, Michael A. Rieger, Michael D. Milsom

    Cell Stem Cell   29 ( 8 )   1273 - 1284.e8   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.stem.2022.06.012

    researchmap

  • Analysis of Immunity against Measles, Mumps, Rubella, and Varicella Zoster in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience Reviewed

    Yoshida S, Fujii N, Kamoi C, Kitamura W, Fujiwara H, Asada N, Nishimori H, Fujii K, Matsuoka KI, Maeda Y

    Acta Med Okayama   76 ( 3 )   247 - 253   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Vaccine-preventable disease (VPD) infections are more severe in immunocompromised hosts. Vaccination against measles, mumps, rubella, and varicella zoster (VZV) (MMRV) is therefore recommended for hematopoietic stem cell transplantation (HCT) recipients. However, studies on adult HCT recipients with VPD infections are limited. At our institution, we have systematically conducted serological MMRV tests as a part of check-up examinations during long-term follow-up (LTFU) after HCT since 2015. This retrospective study aimed to evaluate changes in the serostatus between before and 2 years after allogeneic HCT. Among 161 patients, the pre-transplant seropositivity was 82.7% for measles, 86.8% for mumps, 84.2% for rubella, and 94.3% for VZV. Among 56 patients who underwent LTFU including serological MMRV tests at 2 years after HCT, the percentages maintaining seroprotective antibody levels for measles, mumps, rubella and VZV were 71.5% (40/56), 51.8% (29/56), 48.2% (27/56), and 60.7% (34/56), respectively. Vaccination was recommended for 22 patients, and 12 were vaccinated. Among the 12 vaccinated patients, rates of seroconversion were examined in 2-6 patients for each of the four viruses. They were 100% (3/3) for measles, 33.3% (1/3) for mumps, 50% (3/6) for rubella, and 0% (0/2) for VZV. Further studies are warranted to clarify the effect of vaccination in adult HCT recipients.

    DOI: 10.18926/AMO/63718

    PubMed

    researchmap

  • Successful neutrophil engraftment supported by granulocyte transfusion in adult allogeneic transplant patients with peri-transplant active infection. Reviewed International journal

    Shuntaro Ikegawa, Nobuharu Fujii, Keiko Fujii, Maiko Kimura, Masayuki Matsuda, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis   61 ( 6 )   103453 - 103453   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Active infection at the time of allogeneic hematopoietic stem cell transplantation (HSCT) is a risk for non-relapse mortality (NRM) after HSCT. Granulocyte transfusion (GTX) has been used to prevent or treat life-threatening infections in patients with severe neutropenia. However, data are limited on the clinical benefits of GTX during HSCT. We retrospectively analyzed the transplant outcomes of HSCT patients who had undergone GTX between 2012 and 2020. Altogether, 20 patients with documented infection had received 55 GTXs during HSCT. No adverse events were observed during the GTX infusion. The average number of granulocytes was 0.40 (range, 0.10-1.59) × 109/kg. The median neutrophil increment one day after GTX was 515 (range, -6 to 6630)/μl, which was significantly correlated with the infused granulocyte dose (p = 0.0007). A total of 17 of 20 patients achieved neutrophil engraftment. The number of infused granulocytes tended to higher in clinical responders (p = 0.12), and patients receiving ≥ 0.5 × 109/kg showed trend toward to better transplant outcomes (GTX-high vs. GTX-low, 1-year OS; 33% vs. 11%, p = 0.19. 1-year NRM; 44% vs.77%, p = 0.11). The type of red blood sedimenting agents was significantly correlated with the amounts of granulocyte collection. In conclusion, GTX, especially with a high amount of containing granulocytes, could be a safe bridging therapy for neutrophil engraftment after HSCT in patients with active infection.

    DOI: 10.1016/j.transci.2022.103453

    PubMed

    researchmap

  • Low hematocrit reduces the efficiency of CD34+ cell collection when using the Spectra Optia continuous mononuclear cell collection procedure. Reviewed International journal

    Takumi Kondo, Nobuharu Fujii, Keiko Fujii, Yuichi Sumii, Tomohiro Urata, Maiko Kimura, Masayuki Matsuda, Shuntaro Ikegawa, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   62 ( 5 )   1065 - 1072   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: CD34+ cell collection efficiency (CE) is the determining factor when calculating processed blood volume (PBV) for leukapheresis (LP). However, the factors affecting CE in the continuous mononuclear cell collection (cMNC) protocol performed by the Spectra Optia apheresis system are not well established. STUDY DESIGN AND METHODS: We retrospectively collected the data from 147 consecutive apheresis procedures across 106 healthy donors and 27 patients completed between July 2016 and December 2020 at the Okayama University Hospital. All procedures were performed using the Optia cMNC protocol. RESULTS: The median CD34+ CE2 was significantly higher in the donor samples (64.3%) than in the patient samples (46.8%) (p < .0001). WBC counts, hematocrit, and platelet counts were all significantly higher in the donors than in the patients, and there was a moderate positive correlation between CD34+ CE2 and hematocrit (r = .47, p < .0001), with the equation of the line being y = 1.23x + 12.23. In contrast, there was only a very weak correlation between CD34+ CE2 and WBC or platelet count. In addition, low hematocrit correlated with an increased time to interface formation. CONCLUSION: These data revealed the negative impact of low hematocrit on the efficiency of CD34+ cell collection when using the Optia cMNC protocol and suggest that hematocrit values should also be considered when determining PBV.

    DOI: 10.1111/trf.16856

    PubMed

    researchmap

  • 【(新規)抗腫瘍薬〜光と影〜】モガムリズマブ投与後に移植片対宿主病が重症化した成人T細胞白血病の3例

    横山 恵美, 山崎 修, 淺田 騰, 吉野 正, 森実 真

    皮膚病診療   44 ( 5 )   414 - 419   2022.5

     More details

    Language:Japanese   Publisher:(株)協和企画  

    <文献概要>症例のポイント ・モガムリズマブ投与後に移植片対宿主病(graft-versus-host disease:GVHD)が増悪しStevens-Johnson症候群を呈した成人T細胞白血病(adult T-cell leukemia:ATL)の3例について報告した.・3例とも病理組織学的に液状変性とともに海綿状態を呈した点が特徴的であった.・モガムリズマブによる皮膚障害が生じたATLは予後がよいとされるが,自験例では皮膚にはATLは再燃しなかったものの,3例中2例は他臓器のATLの増悪のため永眠された.

    researchmap

  • Chronic active Epstein–Barr virus infection presenting as refractory chronic sinusitis Reviewed

    Wataru Kitamura, Hideaki Fujiwara, Akifumi Matsumura, Takaya Higaki, Rei Shibata, Tomohiro Toji, Soichiro Fujii, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    International Journal of Hematology   116 ( 1 )   139 - 145   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    A 44-year-old Japanese man presented with fever and sore throat. He had a history of refractory chronic sinusitis that did not respond to several years of pharmacotherapy, and underwent endoscopic sinus surgery (ESS) 5 months prior to his presentation, but his symptoms persisted. A biopsy specimen was taken from the right nasal cavity, and extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) was diagnosed. Two years after complete remission was achieved by chemoradiation therapy, he developed hemophagocytic lymphohistiocytosis (HLH) without recurrence of ENKTL. Epstein-Barr virus (EBV)-DNA copy number was relatively high and EBV-infected lymphocytes (CD8 + T cells) were detected in the peripheral blood. Pathological review of the biopsy specimens taken during ESS showed that CD8 + T cells with slightly atypia infiltrating the stroma were EBV positive. These findings suggested that the patient had underlying chronic active EBV infection (CAEBV) that caused the refractory chronic sinusitis, eventually developed into ENKTL, and also caused HLH. Clinicians should consider adult-onset CAEBV in the differential diagnosis of patients with refractory chronic sinusitis.

    DOI: 10.1007/s12185-022-03306-y

    PubMed

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s12185-022-03306-y/fulltext.html

  • Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group Reviewed

    Wataru Kitamura, Nobuharu Fujii, Yuichiro Nawa, Keigo Fujishita, Hiroyuki Sugiura, Takanori Yoshioka, Yuki Fujiwara, Yoshiaki Usui, Keiko Fujii, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    International Journal of Hematology   115 ( 4 )   515 - 524   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    BACKGROUND: Previous studies have revealed that relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be predicted by monitoring Wilms' tumor 1 (WT1) mRNA expression. However, only a few studies have investigated patients who received human leukocyte antigen-haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCY-haplo). In this study, we investigated the relationship between WT1 mRNA levels and clinical outcomes in the PTCY-haplo group, and compared them with those in the conventional graft-versus-host disease prophylaxis group (conventional group). METHODS: We retrospectively analyzed 130 patients who received their first allo-HSCT between April 2017 and December 2020, including 26 who received PTCY-haplo. RESULTS: The WT1 mRNA expression level at day + 30 after allo-HSCT associated with increased risk of 1-year cumulative incidence of relapse (CIR) was ≥ 78 copies/μg RNA in the conventional group (p < 0.01) and ≥ 50 copies/μg RNA in the PTCY-haplo group (p = 0.03). CONCLUSIONS: The appropriate cutoff level of WT1 mRNA at day + 30 after allo-HSCT for predicting prognosis in patients treated with PTCY-haplo may be < 50 copies/μg RNA.

    DOI: 10.1007/s12185-022-03290-3

    PubMed

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s12185-022-03290-3/fulltext.html

  • Sequential Combination of FLAM and Venetoclax plus Azacitidine to Bridge to Cord Blood Transplantation in a Patient with Primary Induction Failure Acute Myeloid Leukemia. Reviewed International journal

    Hiroyuki Murakami, Ken-Ichi Matsuoka, Takeru Asano, Takashi Moriyama, Akifumi Matsumura, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Tomohiro Toji, Tadashi Yoshino, Yoshinobu Maeda

    Case reports in oncology   15 ( 3 )   974 - 979   2022

     More details

    Language:English  

    Venetoclax (VEN) is an oral B-cell lymphoma-2 (BCL-2) inhibitor that has been widely used to treat various hematological disorders. Recent studies have demonstrated that VEN in combination with fludarabine-enhanced high-dose cytarabine (FLA) is effective for treating relapsed or refractory acute myeloid leukemia (AML). In the combination therapy, salvage chemotherapy and VEN are basically concurrently administrated; however, further optimization may enable the treatment to apply to larger numbers of patients with various clinical backgrounds. Here, we describe a case of refractory AML treated with a sequential combination of the intensive chemotherapy (fludarabine, cytarabine, and mitoxantrone; FLAM) and VEN/AZA to bridge to an unrelated cord blood transplantation (uCBT). By continuously adding VEN/AZA after FLAM, the patient achieved morphologic leukemia free state with only minor toxicities. Blood cell counts did not recover until the time of transplantation because of the deep myelosuppression caused by the treatment sequence, but the infection risk was safely managed during this period. After engraftment, maintenance therapy with VEN/AZA was performed, and the patient has survived without disease recurrence for over 9 months after transplantation. Our case suggests that bridging therapy with VEN and AZA from the time of the last chemotherapy to allogeneic transplantation may provide an effective and tolerable treatment strategy for refractory AML. Further studies of larger numbers of cases are needed to validate the effectiveness of this treatment.

    DOI: 10.1159/000526697

    PubMed

    researchmap

  • Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy Reviewed International journal

    Kazuhito Yamamoto, Atsushi Shinagawa, Courtney D DiNardo, Keith W Pratz, Kenichi Ishizawa, Toshihiro Miyamoto, Norio Komatsu, Yasuhiro Nakashima, Chikashi Yoshida, Noriko Fukuhara, Kensuke Usuki, Takahiro Yamauchi, Noboru Asada, Norio Asou, Ilseung Choi, Yasushi Miyazaki, Hideyuki Honda, Sumiko Okubo, Misaki Kurokawa, Ying Zhou, Jiuhong Zha, Jalaja Potluri, Itaru Matsumura

    Japanese Journal of Clinical Oncology   52 ( 1 )   29 - 38   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Oxford University Press (OUP)  

    <title>Abstract</title>
    <sec>
    <title>Background</title>
    The phase 3 VIALE-A trial (NCT02993523) reported that venetoclax-azacitidine significantly prolonged overall survival compared with placebo-azacitidine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy. Herein, efficacy and safety of venetoclax-azacitidine are analyzed in the Japanese subgroup of VIALE-A patients.


    </sec>
    <sec>
    <title>Methods</title>
    Eligible Japanese patients were randomized 2:1 to venetoclax-azacitidine (N = 24) or placebo-azacitidine (N = 13). Primary endpoints for Japan were overall survival and complete response (CR) + CR with incomplete hematologic recovery (CRi). Venetoclax (target dose 400 mg) was given orally once daily. Azacitidine (75 mg/m2) was administered subcutaneously or intravenously on Days 1–7 of each 28-day cycle.


    </sec>
    <sec>
    <title>Results</title>
    Median follow-up was 16.3 months (range, 1.0–20.3). Median overall survival was not reached with venetoclax-azacitidine (hazard ratio 0.409 and 95% confidence interval: 0.151, 1.109); overall survival estimate was higher with venetoclax-azacitidine than placebo-azacitidine at 12 (67 and 46%) and 18 months (57 and 31%), respectively. CR and CRi rates were 67% with venetoclax-azacitidine and 15% with placebo-azacitidine. Most common any-grade adverse events were febrile neutropenia (79 and 39%), thrombocytopenia (54 and 77%), constipation (54 and 54%) and decreased appetite (54 and 38%) in the venetoclax-azacitidine and placebo-azacitidine arms, respectively. Only 1 patient in the venetoclax-azacitidine arm, and no patients in the placebo-azacitidine arm, had grade 4 febrile neutropenia that led to treatment discontinuation.


    </sec>
    <sec>
    <title>Conclusions</title>
    This Japanese subgroup analysis of VIALE-A demonstrates comparable safety and efficacy outcomes compared with the global study and supports venetoclax-azacitidine as first-line standard-of-care for Japanese treatment-naive patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.


    </sec>

    DOI: 10.1093/jjco/hyab170

    PubMed

    researchmap

  • Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature Reviewed

    Wataru Kitamura, Noboru Asada, Tetsuya Tabata, Rei Shibata, Tatsuya Nishi, Yuka Kato, Hiroki Takasuka, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Nobuharu Fujii, Ken-ichi Matsuoka, Katsuyuki Kiura, Tadashi Yoshino, Yoshinobu Maeda

    Journal of Clinical and Experimental Hematopathology   62 ( 1 )   35 - 40   2021.11

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japanese Society for Lymphoreticular Tissue Research  

    Marginal zone lymphoma (MZL) arising from the anterior mediastinum is rare. In the majority of reported cases, the tumor was incidentally discovered, reflecting its indolent clinical features. We present a 38-year-old woman who had no medical history, and presented with a bulky anterior mediastinal tumor complicated by life-threatening compression of the vasculature and bronchi. Biopsy specimens of the neoplasm suggested transformed diffuse large B-cell lymphoma (DLBCL) from MZL. To our best knowledge, this is the first case report of anterior mediastinum MZL associated with an aggressive clinical course and life-threatening complications likely due to transformation to DLBCL.

    DOI: 10.3960/jslrt.21010

    PubMed

    researchmap

  • Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Reviewed

    Hiroki Kobayashi, Noboru Asada, Yuria Egusa, Tomoka Ikeda, Misa Sakamoto, Masaya Abe, Daisuke Ennishi, Masahiro Sakata, Akinobu Takaki, Soichiro Kawahara, Yusuke Meguri, Hisakazu Nishimori, Nobuharu Fujii, Ken-Ichi Matsuoka, Yasuharu Sato, Tadashi Yoshino, Yoshinobu Maeda

    International journal of hematology   114 ( 3 )   401 - 407   2021.9

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is a rare indolent B-cell neoplasm, and a gain-of-function mutation in the myeloid differentiation primary response 88 (MYD88), L265P, is a commonly recurring mutation in patients with WM/LPL. Histological transformation of WM/LPL to an aggressive lymphoma such as diffuse large B-cell lymphoma (DLBCL) is rare, and transformed DLBCL has a worse prognosis than de novo DLBCL, partly because transformed DLBCL is mostly classified as non-germinal center B-cell-like (non-GCB) subtype. We herein describe a 75-year-old man with DLBCL with a history of WM/LPL. DLBCL in this patient showed the GCB subtype, and the light chain restriction of DLBCL was different from that of the antecedent WM/LPL, indicating that the two types of lymphoma cells had distinctive origins. However, DLBCL in this patient harbored the MYD88 L265P mutation, and polymerase chain reaction and Sanger sequencing of the DLBCL and WM/LPL for immunoglobulin heavy chain gene rearrangement suggested a clonal relationship between the two lymphomas. Since the outcome of transformed DLBCL is worse than for de novo DLBCL, it is important to evaluate the clonal relationship between primary WM/LPL and the corresponding transformed DLBCL, even if the DLBCL expresses a GCB subtype or discordant light chain restriction.

    DOI: 10.1007/s12185-021-03157-z

    PubMed

    researchmap

  • Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression. Reviewed International journal

    Makoto Nakamura, Yusuke Meguri, Shuntaro Ikegawa, Takumi Kondo, Yuichi Sumii, Takuya Fukumi, Miki Iwamoto, Yasuhisa Sando, Hiroyuki Sugiura, Noboru Asada, Daisuke Ennishi, Shuta Tomida, Emi Fukuda-Kawaguchi, Yasuyuki Ishii, Yoshinobu Maeda, Ken-Ichi Matsuoka

    Scientific reports   11 ( 1 )   13125 - 13125   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Posttransplantation cyclophosphamide (PTCy) has become a popular option for haploidentical hematopoietic stem cell transplantation (HSCT). However, personalized methods to adjust immune intensity after PTCy for each patient's condition have not been well studied. Here, we investigated the effects of reducing the dose of PTCy followed by α-galactosylceramide (α-GC), a ligand of iNKT cells, on the reciprocal balance between graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) effect. In a murine haploidentical HSCT model, insufficient GVHD prevention after reduced-dose PTCy was efficiently compensated for by multiple administrations of α-GC. The ligand treatment maintained the enhanced GVL effect after reduced-dose PTCy. Phenotypic analyses revealed that donor-derived B cells presented the ligand and induced preferential skewing to the NKT2 phenotype rather than the NKT1 phenotype, which was followed by the early recovery of all T cell subsets, especially CD4+Foxp3+ regulatory T cells. These studies indicate that α-GC administration soon after reduced-dose PTCy restores GVHD-preventing activity and maintains the GVL effect, which is enhanced by reducing the dose of PTCy. Our results provide important information for the development of a novel strategy to optimize PTCy-based transplantation, particularly in patients with a potential relapse risk.

    DOI: 10.1038/s41598-021-92526-z

    PubMed

    researchmap

  • Effects of Gram-negative Rod Blood Stream Infection on Acute GVHD in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-institute Analysis. Reviewed

    Masaaki Nishinohara, Hisakazu Nishimori, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Ken-Ichi Matsuoka, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    Acta medica Okayama   75 ( 3 )   279 - 287   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A bloodstream infection (BSI) is the most common serious infectious complication of hematopoietic stem cell transplantation (HSCT). BSI promotes an inflammatory state, which exacerbates acute graft-versus-host disease (GVHD). We investigated whether a Gram-negative rod bloodstream infection (GNR-BSI), which develops early after allo-HSCT, affected the onset or exacerbated acute GVHD in 465 patients who underwent allo-HSCT from 1995 through 2015 at a single institution. Eighty-eight patients (19%) developed BSI during the study period. Among the cultures, 50 (57%) were Gram-positive cocci (GPC) and 31 (35%) were GNR. Of the 465 patients, 187 (40%) developed acute GVHD of grade II or higher within the first 100 days post-allogeneic HSCT: 124 (27%) had acute GVHD grade II, 47 (10%) had grade III, and 16 (3%) had grade IV. Multivariate analysis revealed that GNR-BSI was a significant risk factor for grade II-IV acute GVHD (grade II-IV: hazard ratio [HR] 1.75, 95% confidence interval [CI] 1.03-2.97; grade III-IV: HR 2.37, 95% CI 1.03-5.43). These results suggest that GNR-BSI may predict the onset and exacerbation of acute GVHD.

    DOI: 10.18926/AMO/62219

    PubMed

    researchmap

  • Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype Presenting as Chorea during Treatment: A Case Report and Literature Review. Reviewed

    Wataru Kitamura, Daisuke Ennishi, Ryoya Yukawa, Ryo Sasaki, Chikamasa Yoshida, Hiroki Takasuka, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Koji Abe, Tadashi Yoshino, Yoshinobu Maeda

    Internal medicine (Tokyo, Japan)   60 ( 19 )   3155 - 3160   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 72-year-old man presented with chorea while undergoing treatment for recurrence of nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype. An examination by brain N-isopropyl-p-iodoamphetamine (123I-IMP)-single photon emission computed tomography (SPECT) revealed no abnormalities other than a decreased cerebral blood flow (CBF) in the left striatum. After four courses of salvage chemotherapy, his clinical symptoms and asymmetric cerebral perfusion improved, suggesting that the decreased CBF had caused chorea. The significance of brain SPECT has not been fully clarified in patients with chorea-associated malignant lymphoma, warranting further investigations. Brain SPECT is an alternative approach to identify abnormalities in such patients.

    DOI: 10.2169/internalmedicine.7180-21

    PubMed

    researchmap

  • Laparoscopic Hepatectomy for the Patient with Hemophilia A with High Titer Factor VIII Inhibitor. Reviewed

    Tatsuo Matsuda, Yuzo Umeda, Kazuhiro Yoshida, Tadakazu Matsuda, Masatoshi Uno, Masaya Abe, Noboru Asada, Yoshinobu Maeda, Takahito Yagi, Toshiyoshi Fujiwara

    Acta medica Okayama   75 ( 2 )   199 - 204   2021.4

     More details

    Language:English  

    We present the first case of laparoscopic left lateral segmentectomy for hepatocellular carcinoma (HCC) in a patient with hemophilia A, acquired hepatitis C, and high-titer factor VIII inhibitor, which was confirmed by preoperative diagnosis. He underwent laparoscopic left lateral segmentectomy with the administration of recombinant activated factor VII. Surgery could be performed with reduced intraoperative hemorrhage. He experienced postoperative intra-abdominal wall hemorrhage, which was successfully managed with red cell concentrates transfusion and administration of recombinant activated factor VII. Laparoscopic hepatectomy can be applied for hemophilia patients with high titer inhibitors.

    DOI: 10.18926/AMO/61901

    PubMed

    researchmap

  • FGF-23 from erythroblasts promotes hematopoietic progenitor mobilization. Reviewed International journal

    Shinichi Ishii, Tomohide Suzuki, Kanako Wakahashi, Noboru Asada, Yuko Kawano, Hiroki Kawano, Akiko Sada, Kentaro Minagawa, Yukio Nakamura, Seiya Mizuno, Satoru Takahashi, Toshimitsu Matsui, Yoshio Katayama

    Blood   137 ( 11 )   1457 - 1467   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Fibroblast growth factor 23 (FGF-23) hormone is produced by bone-embedded osteocytes and regulates phosphate homeostasis in kidneys. We found that administration of granulocyte colony-stimulating factor (G-CSF) to mice induced a rapid, substantial increase in FGF-23 messenger RNA in bone marrow (BM) cells. This increase originated mainly from CD45-Ter119+CD71+ erythroblasts. FGF-23 protein in BM extracellular fluid was markedly increased during G-CSF-induced hematopoietic progenitor cell (HPC) mobilization, but remained stable in the blood, with no change in the phosphate level. Consistent with the BM hypoxia induced by G-CSF, low oxygen concentration induced FGF-23 release from human erythroblast HUDEP-2 cells in vitro. The efficient mobilization induced by G-CSF decreased drastically in both FGF-23-/- and chimeric mice with FGF-23 deficiency, only in hematopoietic cells, but increased in osteocyte-specific FGF-23-/- mice. This finding suggests that erythroblast-derived, but not bone-derived, FGF-23 is needed to release HPCs from BM into the circulation. Mechanistically, FGF-23 did not influence CXCL-12 binding to CXCR-4 on progenitors but interfered with their transwell migration toward CXCL-12, which was canceled by FGF receptor inhibitors. These results suggest that BM erythroblasts facilitate G-CSF-induced HPC mobilization via FGF-23 production as an intrinsic suppressor of chemoattraction.

    DOI: 10.1182/blood.2020007172

    PubMed

    researchmap

  • Author Correction: 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy. International journal

    Yasuhisa Sando, Ken-Ichi Matsuoka, Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Hiroyuki Sugiura, Makoto Nakamura, Miki Iwamoto, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Atae Utsunomiya, Takashi Oka, Yoshinobu Maeda

    Scientific reports   11 ( 1 )   6420 - 6420   2021.3

     More details

  • Pretransplant nivolumab further enhanced Treg expansion after posttransplant cyclophosphamide; another aspect for immune tolerance by PTCy after nivolumab. International journal

    Shuntaro Ikegawa, Yusuke Meguri, Kentaro Mizuhara, Takuya Fukumi, Hiroki Kobayashi, Yuichi Sumii, Takumi Kondo, Yasuhisa Sando, Miki Iwamoto, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yuka Fujisawa, Toshi Imai, Yoshinobu Maeda, Ken-Ichi Matsuoka

    Leukemia   35 ( 3 )   929 - 931   2021.3

     More details

  • Histologic Transformation from Follicular Lymphoma to Diffuse Large B-cell Lymphoma Detected during Colonoscopy. Reviewed

    Masaya Iwamuro, Yasushi Yamasaki, Takehiro Tanaka, Noboru Asada, Ken-Ichi Matsuoka, Sakiko Hiraoka, Yoshiro Kawahara, Hiroyuki Okada

    Acta medica Okayama   75 ( 5 )   625 - 629   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 77-year-old Japanese woman who had been treated for follicular lymphoma for 8 years developed abdominal pain and intra-abdominal lymphadenopathies. Colonoscopy revealed an elevated lesion in the rectum, which presented as two humps with erosions. A diagnosis of histologic transformation of follicular lymphoma to diffuse large B-cell lymphoma was made by endoscopic biopsy. This case underscores the importance of endoscopy examinations and biopsy of newly emerged gastrointestinal lesions for the prompt diagnosis of histologic transformation, since salvage chemotherapy must be initiated quickly in such cases.

    DOI: 10.18926/AMO/62775

    PubMed

    researchmap

  • Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report. Reviewed International journal

    Masaya Abe, Nobuharu Fujii, Kentaro Mizuhara, Tomohiro Urata, Yuichi Sumii, Yuki Fujiwara, Keisuke Seike, Yasuhisa Sando, Makoto Nakamura, Keiko Fujii, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Leukemia research reports   15   100241 - 100241   2021

     More details

    Language:English  

    Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.

    DOI: 10.1016/j.lrr.2021.100241

    PubMed

    researchmap

  • 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy Reviewed International journal

    Yasuhisa Sando, Ken-ichi Matsuoka, Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Hiroyuki Sugiura, Makoto Nakamura, Miki Iwamoto, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Atae Utsunomiya, Takashi Oka, Yoshinobu Maeda

    Scientific Reports   10 ( 1 )   17237 - 17237   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    <title>Abstract</title>
    Photodynamic therapy (PDT) is an emerging treatment for various solid cancers. We recently reported that tumor cell lines and patient specimens from adult T cell leukemia/lymphoma (ATL) are susceptible to specific cell death by visible light exposure after a short-term culture with 5-aminolevulinic acid, indicating that extracorporeal photopheresis could eradicate hematological tumor cells circulating in peripheral blood. As a bridge from basic research to clinical trial of PDT for hematological malignancies, we here examined the efficacy of ALA-PDT on various lymphoid malignancies with circulating tumor cells in peripheral blood. We also examined the effects of ALA-PDT on tumor cells before and after conventional chemotherapy. With 16 primary blood samples from 13 patients, we demonstrated that PDT efficiently killed tumor cells without influencing normal lymphocytes in aggressive diseases such as acute ATL. Importantly, PDT could eradicate acute ATL cells remaining after standard chemotherapy or anti-CCR4 antibody, suggesting that PDT could work together with other conventional therapies in a complementary manner. The responses of PDT on indolent tumor cells were various but were clearly depending on accumulation of protoporphyrin IX, which indicates the possibility of biomarker-guided application of PDT. These findings provide important information for developing novel therapeutic strategy for hematological malignancies.

    DOI: 10.1038/s41598-020-74174-x

    PubMed

    researchmap

    Other Link: http://www.nature.com/articles/s41598-020-74174-x

  • Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease Reviewed International journal

    Miki Iwamoto, Shuntaro Ikegawa, Takumi Kondo, Yusuke Meguri, Makoto Nakamura, Yasuhisa Sando, Hiroyuki Sugiura, Yuichi Sumii, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Misako Shibakura, Yoshinobu Maeda, Ken-ichi Matsuoka

    Bone Marrow Transplantation   56 ( 4 )   956 - 959   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1038/s41409-020-01100-0

    PubMed

    researchmap

    Other Link: http://www.nature.com/articles/s41409-020-01100-0

  • Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy Reviewed

    Kentaro Mizuhara, Nobuharu Fujii, Yusuke Meguri, Takahide Takahashi, Michinori Aoe, Makoto Nakamura, Keisuke Seike, Yasuhisa Sando, Keiko Fujii, Masaya Abe, Yuichi Sumii, Tomohiro Urata, Yuki Fujiwara, Kyosuke Saeki, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    International Journal of Hematology   112 ( 3 )   422 - 426   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    Post-transplant lymphoproliferative disorder (PTLD) is one of the most serious complications of allogeneic hematopoietic stem cell transplantation (HSCT). Rituximab is effective for PTLD; however, rituximab can produce adverse effects, including hypogammaglobulinemia. Here, we present the case of an 18-year-old female with refractory cytopenia of childhood who developed persistent selective hypogammaglobulinemia with low immunoglobulin G (IgG) 2 and IgG4 levels and monoclonal protein after rituximab therapy against probable PTLD. Despite B-cell recovery, the serum IgG levels gradually declined, reaching < 300 mg/dL at 33 months after rituximab treatment. In addition, class-switched memory (CD27 + IgD -) B cells were limited in phenotypic analysis. These findings suggest that peri-HSCT rituximab may contribute to an abnormal B-cell repertoire induced by impaired immunoglobulin class switch.

    DOI: 10.1007/s12185-020-02886-x

    PubMed

    researchmap

    Other Link: http://link.springer.com/article/10.1007/s12185-020-02886-x/fulltext.html

  • Allogeneic hematopoietic stem cell transplantation in a prior lung transplant recipient Reviewed

    Yuki Fujiwara, Ken-ichi Matsuoka, Miki Iwamoto, Yuichi Sumii, Masaya Abe, Kentaro Mizuhara, Tomohiro Urata, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Junichi Sugita, Hajime Kobayashi, Takahiro Oto, Yoshinobu Maeda

    International Journal of Hematology   112 ( 6 )   871 - 877   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    Hematological diseases after solid organ transplant (SOT) are an emerging issue as the number of long-term SOT survivors increases. Expertise in managing patients requiring allogeneic hematopoietic stem cell transplantation (HSCT) after SOT from independent donors is needed; however, clinical reports of HSCT after SOT are limited, and the feasibility and risk are not well understood. In particular, HSCT in prior lung transplant recipients is thought to be complicated as the lung is immunologically distinct and is constantly exposed to the surrounding environment. Herein, we describe a case of successful HSCT in a patient with myelodysplastic syndromes who had previously received a lung transplant from a deceased donor for bronchiolitis obliterans syndrome. Reports about cases of HSCT after lung transplant are quite rare; thus, we discuss the mechanisms of immune tolerance through the clinical course of our case. This case suggests that HSCT after SOT can be considered a therapeutic option in cases where the transplanted organ is functionally retained and the hematological disease is in remission.

    DOI: 10.1007/s12185-020-02967-x

    PubMed

    researchmap

    Other Link: http://link.springer.com/article/10.1007/s12185-020-02967-x/fulltext.html

  • 原発性マクログロブリン血症から形質転換したGerminal Center B-cellタイプのびまん性大細胞型B細胞リンパ腫の症例

    小林 宏紀, 淺田 騰, 遠西 大輔, 阿部 将也, 池田 知佳, 坂本 美彩, 江草 侑厘安, 廻 勇輔, 西森 久和, 藤井 伸治, 松岡 賢市, 佐藤 康晴, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌   60   82 - 82   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Intestinal Diffuse Large B-Cell Lymphoma in a Patient with Systemic Lupus Erythematosus Reviewed International journal

    Masaya Iwamuro, Takahide Takahashi, Yoko Ota, Takehiro Tanaka, Noboru Asada, Shuya Yano, Mayu Uka, Rei Nakamura, Yuki Baba, Seiji Kawano, Yoshiro Kawahara, Hiroyuki Okada

    Case Reports in Gastrointestinal Medicine   2020   1 - 5   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Hindawi Limited  

    A 44-year-old Japanese woman with systemic lupus erythematosus (SLE) presented to our hospital with abdominal pain. Radiological and endoscopic examinations led to the diagnosis of diffuse large B-cell lymphoma of the jejunum, which was subsequently resected. Patients with SLE reportedly have an increased risk of non-Hodgkin lymphoma, as demonstrated by our patient. Hence, lymphoma should be considered in the differential diagnosis of neoplastic lesions emerging in SLE patients. In addition, flow cytometry using endoscopically biopsied fragments is useful for the immediate diagnosis of lymphoma, leading to timely and accurate preoperative staging.

    DOI: 10.1155/2020/7947540

    PubMed

    researchmap

    Other Link: http://downloads.hindawi.com/journals/crigm/2020/7947540.xml

  • Efficacy of HLA virtual cross‐matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation Reviewed International journal

    Keisuke Seike, Nobuharu Fujii, Naomi Asano, Shigenori Ohkuma, Yasushi Hirata, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kazunori Naito, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Kazuo Tsubaki, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   60 ( 3 )   473 - 478   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    BACKGROUND: Cross-matched platelet (cross-matched PLT) transfusion is effective for immune-mediated platelet transfusion refractoriness (PTR), but is more costly and time-consuming for physical cross-match than using standard PLT units. Recent studies have reported the utility of human leucocyte antigens (HLA) virtual cross-matched PLT (HLA-matched PLT) that is defined as HLA-A/B matched or no antibody against donor-specific antigen. Here, we evaluated the effect of HLA-matched PLTs for PTR in post hematopoietic stem cell transplant (HSCT) recipients. STUDY DESIGN AND METHODS: Our study included a total of 241 PLTs in 16 patients who underwent HSCT at Okayama University Hospital between 2010 and 2017, receiving either HLA-matched or cross-matched PLTs. We calculated the 24-hour corrected count increments (CCI-24) to evaluate the effect of PLTs. A CCI-24 ≥ 4500 was considered to be a successful transfusion. RESULTS: We analyzed 139 cross-matched PLTs and 102 HLA-matched PLTs. In the immune-mediated PTR, the rate of successful transfusion was 60.5% for cross-matched PLT and 63.4% for HLA-matched PLT (p = 0.825). On the other hand, the median CCI-24 for cross-matched PLT transfusions and HLA-matched PLT transfusions were 1856 and 5824 (p < 0.001), with a success rate of 28.1 and 54.1% in cases with non-immune-mediated PTR, respectively (p = 0.001). CONCLUSION: The effectiveness of HLA-matched PLT is not inferior to cross-matched PLT. This result indicates that physical cross-match can be omitted in post HSCT PTR.

    DOI: 10.1111/trf.15664

    PubMed

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/trf.15664

  • Salvage Haploidentical Transplantation Using Low-dose ATG for Early Disease Relapse after First Allogeneic Transplantation: A Retrospective Single-center Review. Reviewed

    Okamoto S, Matsuoka KI, Sakamoto M, Usui Y, Fujiwara Y, Kondo T, Tani K, Saeki K, Meguri Y, Asada N, Ennishi D, Nishimori H, Fujii K, Fujii N, Maeda Y

    Acta medica Okayama   73 ( 2 )   161 - 171   2019.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Second allogeneic stem cell transplantation (allo-SCT) is a potentially curative therapy for patients who relapse after first allo-SCT. Human leukocyte antigen (HLA)-haploidentical related donors provide the broad opportunity to conduct second SCT at the appropriate time, but the efficacy of second SCT from haploidentical donors after relapse has not been established. We retrospectively analyzed the records of 33 patients who underwent second SCT. Twenty patients underwent haplo-SCT with low-dose antithymocyte globulin (ATG), and the other 13 patients underwent conventional- SCTs, including HLA-matched related peripheral blood, unrelated bone marrow or cord blood. Three years after the second SCT, the overall survival (OS) and progression-free survival (PFS) of all patients were 32.5% and 23.9%. Multivariate analyses indicated that non-complete response at second SCT, less than 1-year interval to relapse after first- SCT, and total score ≥ 3 on the hematopoietic cell transplantation-specific comorbidity index were significantly associated with a lower PFS rate. The haplo- and conventional- SCT groups showed equivalent results regarding OS, PFS, cumulative incidences of relapse, non-relapse mortality and graft-versus-host disease. The neutropenic period after transplantation was significantly shorter in haplo- SCT than conventional- SCT (10.5 days vs. 16 days, p=0.001). Our analysis revealed that haplo-SCT could be an alternative therapeutic option for relapsed patients after first SCT.

    DOI: 10.18926/AMO/56652

    PubMed

    researchmap

  • Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. Reviewed International journal

    Wakahashi K, Minagawa K, Kawano Y, Kawano H, Suzuki T, Ishii S, Sada A, Asada N, Sato M, Kato S, Shide K, Shimoda K, Matsui T, Katayama Y

    Blood   133 ( 15 )   1619 - 1629   2019.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Myelofibrosis in myeloproliferative neoplasms (MPNs) with mutations such as JAK2V617F is an unfavorable sign for uncontrollable disease progression in the clinic and is complicated with osteosclerosis whose pathogenesis is largely unknown. Because several studies have revealed that macrophages are an indispensable supporter for bone-forming osteoblasts, we speculated that macrophages might play a significant role in the proliferation of collagen-producing myofibroblasts in marrow fibrotic tissues. Here, we show that myelofibrosis critically depends on macrophages whose differentiation is skewed by vitamin D receptor (VDR) signaling. In our novel myelofibrosis model established by transplantation of VDR+/+ hematopoietic stem/progenitor cells into VDR-/- mice, donor-derived F4/80+ macrophages proliferated together with recipient-derived α-smooth muscle actin-positive myofibroblasts, both of which comprised fibrotic tissues with an indistinguishable spindle-shaped morphology. Interfering VDR signals, such as low vitamin D diet and VDR deficiency in donor cells as well as macrophage depletion prevented myelofibrosis in this model. These interventions also ameliorated myelofibrosis in JAK2V617F-driven murine MPNs likely in a transforming growth factor-β1- or megakaryocyte-independent manner. These results suggest that VDR and macrophages may be novel therapeutic targets for MPNs with myelofibrosis.

    DOI: 10.1182/blood-2018-09-876615

    PubMed

    researchmap

  • A case report of TAFRO syndrome successfully treated by immunosuppressive therapies with plasma exchange. Reviewed

    Meguri Y, Asada N, Nakasako Y, Kondo E, Kambara Y, Yamamoto A, Masunari T, Sezaki N, Ikeda G, Toji T, Yoshino T, Kiguchi T

    Annals of hematology   98 ( 2 )   537 - 539   2018.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s00277-018-3456-9

    PubMed

    researchmap

    Other Link: http://link.springer.com/content/pdf/10.1007/s00277-018-3456-9.pdf

  • Posttranscriptional Modulation of Cytokine Production in T Cells for the Regulation of Excessive Inflammation by TFL Reviewed

    Kentaro Minagawa, Kanako Wakahashi, Hiroki Kawano, Shinichiro Nishikawa, Chie Fukui, Yuko Kawano, Noboru Asada, Mari Sato, Akiko Sada, Yoshio Katayama, Toshimitsu Matsui

    JOURNAL OF IMMUNOLOGY   192 ( 4 )   1512 - 1524   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER ASSOC IMMUNOLOGISTS  

    Posttranscriptional machinery regulates inflammation and is associated with autoimmunity as well as tumorigenesis in collaboration with transcription factors. We previously identified the tumor suppressor gene transformed follicular lymphoma (TFL) on 6q25 in a patient with follicular lymphoma, which transformed into diffuse large B cell lymphoma. TFL families have a common RNase domain that governs macrophage-mediated inflammation. In human peripheral blood, TFL is dominantly expressed at the glycine-and tryptophan-rich cytoplasmic processing bodies of T lymphocytes, and it is persistently upregulated in activated T cells. To address its physiological role, we established TFL-/- mice in which TFL-/- lymphocytes proliferated more rapidly than TFL+/+ upon stimulation with inappropriate cytokine secretion, including IL-2, IL-6, and IL-10. Moreover, TFL inhibited the synthesis of cytokines such as IL-2, IL-6, IL-10, TNF-alpha, and IL-17a by 3' untranslated region RNA degradation. Experimental autoimmune encephalitis induced in TFL-/- mice demonstrated persistent severe paralysis. CNS-infiltrated CD4(+) T cells in TFL-/- mice contained a higher proportion of Th17 cells than did those in TFL+/+ mice during the resolution phase, and IL17a mRNA levels were markedly increased in TFL-/- cells. These results suggest that TFL may play an important role in attenuating local inflammation by suppressing the infiltration of Th17 cells in the CNS during the resolution phase of experimental autoimmune encephalitis. TFL is a novel gradual and persistent posttranscriptional regulator, and the TFL-driven attenuation of excessive inflammation could contribute to recovery from T cell-mediated autoimmune diseases.

    DOI: 10.4049/jimmunol.1301619

    Web of Science

    PubMed

    researchmap

  • 新しい全自動型血液成分分離装置Spectra Optiaを用いた末梢血幹細胞採取Cobe Spectraと比較して

    藤井 敬子, 淺田 騰, 西森 久和, 山川 美和, 森 繰代, 狩山 由貴, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 岩月 啓氏

    日本輸血細胞治療学会誌   59 ( 1 )   91 - 91   2013.2

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Delayed neutrophil engraftment in cord blood transplantation with intensive administration of mycophenolate mofetil for GVHD prophylaxis Reviewed

    A. Okamura, M. Shimoyama, S. Ishii, K. Wakahashi, N. Asada, H. Kawano, Y. Kawamori, S. Nishikawa, K. Minagawa, Y. Katayama, T. Matsui

    BONE MARROW TRANSPLANTATION   46 ( 1 )   148 - 149   2011.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    DOI: 10.1038/bmt.2010.59

    Web of Science

    PubMed

    researchmap

  • A clinicopathological study of 13 cases of intravascular lymphoma: experience in a single institution over a 9-yr period Reviewed

    Kosei Matsue, Noboru Asada, Masami Takeuchi, Masayuki Yamakura, Shun-Ichi Kimura, Jun Odawara, Takatoshi Aoki

    EUROPEAN JOURNAL OF HAEMATOLOGY   80 ( 3 )   236 - 244   2008.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BLACKWELL PUBLISHING  

    Intravascular lymphoma (IVL) is a rare type of extranodal lymphoma in which the lymphoma cells proliferate exclusively in lumina of small vessels. Here, we report a clinicopathological study of 13 cases IVL diagnosed at our institution between March 1999 and July 2007, and evaluated the clinical characteristics, usefulness of random skin biopsy and response to chemotherapy containing rituximab. Three of 13 patients were diagnosed at autopsy. The most common clinical features were unexplained fever, neurological deterioration, respiratory failure, and poor performance status. Thrombocytopenia, high serum lactate dehydrogenase and soluble interleukin2 receptor levels were the most common laboratory abnormalities. Adrenal tumor was detected in four cases and pituitary involvement was seen in all three autopsied cases and in two surviving patient by brain magnetic resonance imaging. Bone marrow invasion was seen in all 13 cases by bone marrow smear, and it was subtle in trephine biopsy. Immunohistochemical analyses revealed that CD5 was positive in one-third of the cases. Most of the cases were positive for MUM1/IRF, Bcl-2 and negative for CD10 and BCL-6 indicating the postgerminal center cell origin of this peculiar type of lymphoma. On random skin biopsy, the most recent seven patients were diagnosed promptly and chemotherapy containing rituximab was successfully administered. Patients with IVL exhibit the characteristic clinical and immunophenotypic features cited above and the use of random skin biopsy facilitates prompt diagnosis. Early commencement of chemotherapy containing rituximab appears promising for this peculiar lymphoma. As the recent seven patients were diagnosed by random skin biopsy over the past 13 months, the incidence of IVL is thought to be much higher than generally accepted.

    DOI: 10.1111/j.1600-0609.2007.01008.x

    Web of Science

    PubMed

    researchmap

  • Primary amyloidosis associated with IgD-λ M-proteinemia

    KIMURA Shunichi, IWATSUKA Ryota, AOKI Takatoshi, ODAWARA Jun, ASADA Noboru, YAMAKURA Masayuki, TAKEUCHI Masami, MATSUE Kosei

    The Japanese journal of clinical hematology   48 ( 12 )   1555 - 1558   2007.12

     More details

    Language:Japanese   Publisher:「臨床血液」編集部  

    DOI: 10.11406/rinketsu.48.1555

    CiNii Article

    CiNii Books

    researchmap

  • [Primary amyloidosis associated with IgD-lambda M-proteinemia]. Reviewed

    Kimura S, Iwatsuka R, Aoki T, Odawara J, Asada N, Yamakura M, Takeuchi M, Matsue K

    [Rinsho ketsueki] The Japanese journal of clinical hematology   48 ( 12 )   1555 - 1558   2007.12

  • Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis Reviewed

    Mihoko Koseki, Noboru Asada, Hidetaka Uryu, Masami Takeuchi, Hidesaku Asakura, Kosei Matsue

    INTERNATIONAL JOURNAL OF HEMATOLOGY   86 ( 5 )   403 - 406   2007.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER TOKYO  

    The current therapeutic strategy for disseminated intravascular coagulation (DIC) is limited to control of the underlying disease, and methods for the effective management of DIC have not been established. We report the successful use of tranexamic acid (TA) combined with unfractionated heparin in a patient with life-threatening bleeding from the sigmoid colon caused by DIC. A 35-year-old man who had undergone allogeneic bone marrow transplantation for chronic myelogenous leukemia was referred for relapse of his leukemia. The patient was first treated with imatinib at 600 mg/day. Although the disappearance of leukemic cells and a decrease in the BCR/ABL fusion gene were observed, he developed massive bleeding from the sigmoid colon after defecation. A laboratory diagnosis of DIC with prominent fibrinolysis was based on elevated levels of both plasmin-alpha(2)-plasmin inhibitor complex and thrombin-antithrombin III complex. Despite vigorous supportive therapy, including multiple transfusions and aggressive fluid resuscitation, the patient developed hypovolemic shock due to the uncontrollable bleeding. TA combined with unfractionated heparin was instituted to inhibit excessive fibrinolysis. A prompt response was observed soon after the commencement of therapy. No organ dysfunction was observed throughout TA and heparin use. To our knowledge, this report is the first to describe successful treatment with TA combined with heparin for life-threatening intestinal bleeding due to acute DIC associated with hematologic malignancy.

    DOI: 10.1532/IJH97.07059

    Web of Science

    PubMed

    researchmap

  • Intravascular Large B cell Lymphoma(IVL)におけるPET/CTの有用性

    小田原淳, 淺田騰, 青木孝友, 木村俊一, 山倉昌之, 竹内正美, 末永孝生

    臨床血液   48 ( 9 )   982   2007.9

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 悪性リンパ腫における組織学的骨髄浸潤とFDG‐PET/CTの相関:組織型による感度の違い

    山倉昌之, 小田原淳, 青木孝友, 木村俊一, 淺田騰, 竹内正美, 末永孝生

    臨床血液   48 ( 9 )   992   2007.9

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 当院における50歳以上の同種造血幹細胞移植の検討

    青木孝友, 高梨葉子, 小田原淳, 淺田騰, 木村俊一, 山倉昌之, 竹内正美, 末永孝生

    臨床血液   48 ( 9 )   1104   2007.9

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 血管内悪性リンパ腫の診断におけるランダム皮膚生検の有用性

    淺田騰, 小田原淳, 青木孝友, 木村俊一, 山倉昌之, 竹内正美, 末永孝生

    臨床血液   48 ( 9 )   982   2007.9

     More details

    Authorship:Lead author   Language:Japanese  

    J-GLOBAL

    researchmap

  • Identification of cardiac metastasis of primary gastric diffuse large B-cell lymphoma Reviewed

    Masaharu Tsubokura, Noboru Asada, Jun Odawara, Takatoshi Aoki, Masayuki Yamakura, Masami Takeuchi, Kosei Matsue

    British Journal of Haematology   137 ( 3 )   179   2007.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1365-2141.2007.06511.x

    Scopus

    PubMed

    researchmap

  • 18F-fluorodeoxyglucose positron emission tomography for evaluation of intravascular large B-cell lymphoma Reviewed

    Jun Odawara, Noboru Asada, Takatoshi Aoki, Masayuki Yamakura, Masami Takeuchi, Toshihiro Ohuchi, Kosei Matsue

    British Journal of Haematology   136 ( 5 )   684   2007.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1365-2141.2006.06414.x

    Scopus

    PubMed

    researchmap

  • Rapid improvement of hypoxemia by the use of rituximab in patients with pulmonary intravascular lymphoma Reviewed

    Kosei Matsue, Masami Takeuchi, Hidetaka Uryu, Mihoko Koseki, Noboru Asada, Yosinori Kaneko

    LEUKEMIA & LYMPHOMA   48 ( 1 )   197 - 200   2007.1

     More details

    Language:English   Publisher:TAYLOR & FRANCIS LTD  

    DOI: 10.1080/10428190600909487

    Web of Science

    PubMed

    researchmap

  • Picture in Clinical Hematology

    淺田 騰, 松岡 賢市, 小田原 淳, 青木 孝友, 山倉 昌之, 竹内 正美, 末永 孝生

    Rinsho Ketsueki   48 ( 1 )   1 - 1   2007

     More details

    Authorship:Lead author   Language:Japanese   Publisher:一般社団法人 日本血液学会  

    CiNii Article

    researchmap

  • 当院におけるカンジダ血症についての検討

    木村俊一, 淺田騰, 瓜生英尚, 末永考生, 岩渕千太郎, 土井朝子, 細川直登, 岩田健太郎

    感染症学雑誌   80 ( 6 )   783   2006.11

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • [Analysis of serum Aspergillus galactomannan contents conducted at our hospital during the past 2 years]. Reviewed

    Uryu H, Kozeki M, Asada N, Takeuchi M, Suenaga T

    The Japanese journal of antibiotics   59 ( 5 )   413 - 414   2006.10

     More details

  • Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin Reviewed

    K Matsue, H Uryu, M Koseki, N Asada, M Takeuchi

    CLINICAL INFECTIOUS DISEASES   42 ( 6 )   753 - 757   2006.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:UNIV CHICAGO PRESS  

    Background. Micafungin is a newly approved antifungal agent in the echinocandin class that is active against Candida species and Aspergillus species. However, this agent has limited activity against a number of fungi, including Trichosporon species. We describe 4 patients who developed disseminated trichosporonosis during the use of micafungin. No cases of trichosporonosis had been seen in the 2 years prior to January 2003, when micafungin became available in our hospital.
    Methods. We reviewed microbiological records of patients at Kameda General Hospital (Kamogawa City, Chiba, Japan) from 1 January 2002 to 31 July 2005, and identified 4 patients whose blood culture results were positive for Trichosporon species.
    Results. Since January 2003, four patients - 3 with acute myelocytic leukemia and 1 with myelodysplastic syndrome - developed disseminated trichosporonosis while receiving treatment with micafungin with or without amphotericin B. The initial 2 isolates were identified as Trichosporon beigelii, and the later 2 isolates were identified as Trichosporon asahii. All 4 patients received micafungin, and 2 also received amphotericin B concomitantly. Minimal inhibitory concentrations of micafungin were 116 mu g/mL for the 2 isolates available for susceptibility testing. One patient with hematologic recovery (neutrophils &gt; 500 cells/mm(3)) showed elimination of the fungus after receiving treatment with voriconazole. However, the 3 other patients without hematologic or immunological recovery died of disseminated infection.
    Conclusions. The rarity of trichosporonosis in our hospital and its emergence after the introduction of micafungin therapy support the idea that micafungin may exert a significant, selective pressure toward resistant fungi, such as Trichosporon species. Therefore, care should be taken regarding the possibility of trichosporonosis in patients receiving micafungin with or without amphotericin B.

    DOI: 10.1086/500323

    Web of Science

    PubMed

    researchmap

  • Gastrointestinal stromal tumor(GIST)を合併した膿胸関連リンパ腫(PAL)の1例

    浅田 騰, 根本 仁, 森 康雄, 新谷 大悟, 竹内 正美, 末永 孝生

    臨床血液   45 ( 1 )   84 - 85   2004.1

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

▼display all

Books

▼display all

MISC

  • Tisagenlecleucel投与後のステロイド抵抗性CRSに対し、cyclophosphamide投与を行い改善が得られた1例

    守山 喬史, 藤原 英晃, 村上 裕之, 松村 彰文, 大山 矩史, 淺田 騰, 西森 久和, 藤井 敬子, 藤井 伸治, 遠西 大輔, 末次 慶收, 松岡 賢市, 前田 嘉信

    臨床血液   63 ( 6 )   685 - 685   2022.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • ASH meeting report 1)総論

    淺田 騰

    腫瘍内科   28 ( 5 )   474 - 475   2021.11

     More details

    Authorship:Lead author, Corresponding author  

    researchmap

  • Treatment outcome of relapse/refractory DLBCL by tisagenlecleucel

    北村亘, 淺田騰, 藤原英晃, 藤井伸治, 池内一廣, 高須賀裕樹, 大山矩史, 小林宏紀, 福見拓也, 佐伯恭昌, 廻勇輔, 遠西大輔, 西森久和, 藤井敬子, 松岡賢市, 松村卓郎, 今村豊, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集   43rd   2021

  • The effect of live attenuated vaccines after allo-HSCT for adult patients

    鴨井千尋, 鴨井千尋, 吉田将平, 藤井伸治, 藤井伸治, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井敬子, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)   83rd   2021

  • 長期的に赤血球輸血依存状態となった成人ドミナント型βサラセミア患者に対する根治治療としての造血幹細胞移植

    北村亘, 藤井伸治, 藤井伸治, 但馬史人, 高須賀裕樹, 大山矩史, 村上裕之, 木村真衣子, 近藤匠, 松田真幸, 池川俊太郎, 池川俊太郎, 高木尚江, 高木尚江, 藤原英晃, 淺田騰, 遠西大輔, 遠西大輔, 西森久和, 藤井敬子, 松岡賢市, 前田嘉信

    日本輸血細胞治療学会誌   67 ( 2 )   373 - 373   2021

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    J-GLOBAL

    researchmap

  • 移植後シクロホスファミドを用いた血縁者間HLA半合致移植後に最重症遅発性肝類洞閉塞症候群を合併した非定型慢性骨髄性白血病

    北村亘, 藤井伸治, 藤井伸治, 大西秀樹, 高須賀裕樹, 大山矩史, 村上裕之, 木村真衣子, 近藤匠, 松田真幸, 池川俊太郎, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 遠西大輔, 西森久和, 藤井敬子, 藤井敬子, 松岡賢市, 木口亨, 柳井広之, 吉野正, 前田嘉信

    臨床血液   62 ( 6 )   654 - 655   2021

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • Marfan症候群に先天性第XI因子欠乏症とvon Willebrand病(VWD)を合併した患者の心臓弁膜症手術の周術期管理

    大山矩史, 淺田騰, 末澤孝徳, 新谷憲治, 廣田真規, 池内一廣, 北村亘, 高須賀裕樹, 藤原英晃, 遠西大輔, 西森久和, 藤井伸治, 松岡賢市, 笠原真悟, 前田嘉信

    臨床血液   62 ( 6 )   663 - 663   2021

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation (vol 60, pg 473, 2020)

    Keisuke Seike, Nobuharu Fujii, Naomi Asano, Shigenori Ohkuma, Yasushi Hirata, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kazunori Naito, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-ichi Matsuoka, Kazuo Tsubaki, Fumio Otsuka, Yoshinobu Maeda

    TRANSFUSION   60 ( 11 )   2765 - 2765   2020.11

     More details

    Language:English   Publisher:WILEY  

    DOI: 10.1111/trf.15872

    Web of Science

    researchmap

  • 肝膿瘍を合併した急性骨髄性白血病の造血幹細胞移植時に顆粒球輸注が有効であった1例

    谷岡桃子, 福見拓也, 神原由依, 池内一廣, 小林宏紀, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 藤井伸治, 松岡賢市, 前田嘉信

    臨床血液   61 ( 10 )   1529 - 1529   2020

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 造血幹細胞ニッチの機能的多様性

    淺田騰

    臨床血液   2019.6

     More details

    Authorship:Lead author, Corresponding author  

    researchmap

  • 二度の同種造血幹細胞移植に続く脳死肺移植後に骨髄異形成症候群を発症し臍帯血移植を施行した1例

    伊藤 啓, 藤原 悠紀, 住居 優一, 阿部 将也, 水原 健太郎, 浦田 知宏, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 松岡 賢市, 藤井 伸治, 前田 嘉信

    臨床血液   60 ( 5 )   511 - 511   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • EBV陽性びまん性大細胞型B細胞リンパ腫に対する化学療法施行後に血管免疫芽球性T細胞リンパ腫を発症した1例

    渡邊 真衣, 水原 健太郎, 遠西 大輔, 阿部 将也, 住居 優一, 浦田 知宏, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 西森 久和, 松岡 賢市, 藤井 伸治, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌   59   153 - 153   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • Cyclophosphamide(CY)が奏効した難治性TAFRO症候群の一例

    浦田 知宏, 遠西 大輔, 水原 健太郎, 阿部 将也, 住居 優一, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 西森 久和, 藤井 伸治, 藤井 敬子, 佐藤 康晴, 松岡 賢市, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌   59   141 - 141   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    J-GLOBAL

    researchmap

  • 急性骨髄性白血病に対する臍帯血移植後に発症しバンコマイシン髄注と顆粒球輸注が有効であったEnterococcus faecium髄膜炎の1例

    上田 弥生, 水原 健太郎, 松岡 賢市, 阿部 将也, 浦田 知宏, 神原 由依, 住居 優一, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 伸治, 前田 嘉信

    臨床血液   60 ( 5 )   508 - 508   2019.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • 同種造血幹細胞移植後の晩期進行性低IgG血症をきたした1例

    水原健太郎, 藤井伸治, 住居優一, 神原由衣, 浦田知宏, 藤原悠紀, 佐伯恭昌, 廻勇輔, 遠西大輔, 淺田騰, 西森久和, 松岡賢市, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集   41st   2019

  • Prospective Evaluation of Prognostic Relevance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: Results from the JALSG CBF-AML209-KIT Study

    Naomi Kawashima, Yuichi Ishikawa, Yoshiko Atsuta, Isamu Sugiura, Masashi Sawa, Nobuaki Dobashi, Hisayuki Yokoyama, Noriko Doki, Akihiro Tomita, Toru Kiguchi, Shiro Koh, Heiwa Kanamori, Noriyoshi Iriyama, Akio Kohno, Yukiyoshi Moriuchi, Noboru Asada, Daiki Hirano, Kazuto Togitani, Toru Sakura, Maki Hagihara, Tatsuki Tomikawa, Yasuhisa Yokoyama, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-113931

    Web of Science

    researchmap

  • Efficacy of HLA-Matched PLT Transfusions for Platelet Transfusion Refractoriness in HSCT Patients

    Keisuke Seike, Nobuharu Fujii, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Yoshinobu Maeda

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-112365

    Web of Science

    researchmap

  • TFL Deletion Induces Incredible CXCL13 Secretion and Cachexia in Vavp-Bcl2 Transgenic Mice

    Kentaro Minagawa, Kanako Wakahashi, Fukui Chie, Shinichiro Nishikawa, Noboru Asada, Yuko Kawano, Hiroki Kawano, Tomohide Suzuki, Shinichi Ishii, Yoshio Katayama, Toshimitsu Matsui

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-114351

    Web of Science

    researchmap

  • 造血幹細胞移植における患者指定適合血小板輸血の有効性についての検討(Efficacy of HLA-matched PLT transfusion for platelet transfusion refractoriness in HSCT patients)

    清家 圭介, 藤井 伸治, 藤井 敬子, 三道 康永, 中村 真, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 松岡 賢市, 前田 嘉信

    臨床血液   59 ( 9 )   1541 - 1541   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • PD-1阻害薬使用後の自家造血幹細胞移植におけるサイトカイン放出症候群の病態解析(Mechanistic analysis of cytokine release syndrome after autologous HSCT following PD-1 blockade)

    碓井 喜明, 松岡 賢市, 廻 勇輔, 岩本 美紀, 三道 康永, 坂本 真衣子, 藤原 悠紀, 近藤 匠, 谷 勝真, 佐伯 恭昌, 岡本 幸代, 淺田 騰, 西森 久和, 藤井 伸治, 近藤 英生, 前田 嘉信

    臨床血液   59 ( 9 )   1542 - 1542   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 乳房腫脹を契機に診断されたperipheral T-cell lymphoma、with T follicular helper phenotypeの1例

    碓井 喜明, 松岡 賢市, 近藤 匠, 坂本 真衣子, 谷 勝真, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 岡本 幸代, 西森 久和, 近藤 英生, 藤井 伸治, 吉野 正, 前田 嘉信

    臨床血液   59 ( 5 )   633 - 633   2018.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 同種造血幹細胞移植後の好中球減少患者に対する顆粒球輸注療法

    藤井 伸治, 池川 俊太郎, 藤井 敬子, 佐伯 恭昌, 廻 勇輔, 浅田 騰, 西森 久和, 松岡 賢市, 大塚 文男, 前田 嘉信

    日本輸血細胞治療学会誌   64 ( 2 )   453 - 453   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Granulocyte Transfusions for Neutropenic Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

    Shuntaro Ikegawa, Nobuharu Fujii, Keiko Fujii, Yusuke Meguri, Kyosuke Saeki, Noboru Asada, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   24 ( 3 )   S326 - S326   2018.3

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER SCIENCE INC  

    DOI: 10.1016/j.bbmt.2017.12.382

    Web of Science

    researchmap

  • 同種造血幹細胞移植患者におけるStenotrophomonas maltophilia菌血症の死亡リスク因子の検討

    碓井喜明, 淺田騰, 近藤匠, 松田真幸, 坂本真衣子, 谷勝真, 藤原悠紀, 佐伯恭昌, 廻勇輔, 岡本幸代, 西森久和, 松岡賢市, 藤井伸治, 近藤英生, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集   40th   220   2017.12

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Myelin basic proteinが活動性の指標となりえた同種移植後のネララビン関連脊髄炎

    坂本真衣子, 廻勇輔, 松田真幸, 碓井喜明, 近藤匠, 佐伯恭昌, 淺田騰, 西森久和, 松岡賢市, 藤井伸治, 近藤英生, 森原隆太, 山本晃, 木口亨, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集   40th   338   2017.12

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 同種移植後再発に対する2nd HSCTの後方視的解析;Haploidentical移植の有用性の検討

    岡本幸代, 松岡賢市, 坂本真衣子, 碓井喜明, 藤原悠紀, 近藤匠, 松田真幸, 谷勝真, 佐伯恭昌, 廻勇輔, 淺田騰, 西森久和, 藤井伸治, 近藤英生, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集   40th   336   2017.12

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Granulocyte Transfusions for Neutropenic Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

    Shuntaro Ikegawa, Nobuharu Fujii, Keiko Fujii, Yusuke Meguri, Kyosuke Saeki, Noboru Asada, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    BLOOD   130   2017.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    Web of Science

    researchmap

  • SELECTION OF ABO-BLOOD TYPE FOR RED BLOOD CELL TRANSFUSION IN INFANTS AGED UP TO 4 MONTHS WITH MATERNAL ANTI-A AND/OR ANTI-B ANTIBODIES

    Asano Naomi, Fujii Keiko, Fujii Nobuharu, Ogo Hiroaki, Ikeda Toru, Hinokuchi Yuki, Takagi Naoe, Yamakawa Miwa, Yoshioka Takanori, Kobayashi Yujin, Asada Noboru

    JJTC   63 ( 1 )   3 - 8   2017

     More details

    Language:Japanese   Publisher:The Japan Society of Transfusion Medicine and Cell Therapy  

    &lt;p&gt;The existence of maternal anti-A and/or anti-B antibodies has to be clarified in selecting ABO-blood type for red blood cell (RBC) transfusion in infants aged up to 4 months. In Okayama University Hospital, we have not had a standardized policy for ABO-blood type selection based on the results of assays for maternal anti-A and anti-B antibodies in patients. In this study, we retrospectively reviewed the data about selecting ABO-blood type for RBC transfusion in infants aged up to 4 months with anti-A and/or anti-B antibodies between April 2009 and March 2013.&lt;/p&gt;&lt;p&gt;There were 44 cases (14.2%) where maternal anti-A and/or anti-B antibodies were detected by indirect antiglobulin tests among 309 patients of blood type A, B, or AB aged up to 4 months. Blood type O was selected for 24 of the 44 cases, while the same blood type as that reported for the respective patients was selected 20 cases. Hemolysis was not reported in any cases, however, there were 17 cases of positive agglutination in back typing blood tests using the same patients&#039; ABO-blood type by column agglutination technology. This back typing blood test by column agglutination technology that detected maternal anti-A and anti-B IgG antibodies might be useful for determining ABO-blood type for transfusion.&lt;/p&gt;

    DOI: 10.3925/jjtc.63.3

    CiNii Article

    researchmap

  • 生後4カ月以内の乳児における母由来の抗A,抗B抗体検出時の適合血の選択

    浅野尚美, 小郷博昭, 池田亮, 閘結稀, 高木尚江, 山川美和, 吉岡尚徳, 小林優人, 淺田騰, 藤井敬子, 藤井伸治

    日本輸血細胞治療学会誌   63 ( 1 )   3‐8(J‐STAGE)   2017

     More details

    Language:Japanese  

    DOI: 10.3925/jjtc.63.3

    J-GLOBAL

    researchmap

  • Loss of Adrenergic Nerves in the Bone Marrow Microenvironment Drives an Aging HSC Niche Phenotype

    Maria Maryanovich, Ali H. Zahalka, Halley Pierce, Sandra Pinho, Fumio Nakahara, Noboru Asada, Avigdor Leftin, Jan Vijg, Paul S. Frenette

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood.V128.22.169.169

    Web of Science

    researchmap

  • Hematopoietic Stem Cells Fail to Regenerate In Vivo Following Inflammatory Stress

    Ruzhica Bogeska, Paul Kaschutnig, Stella Paffenholz, Julia Maassen, Jan-Philipp Mallm, Felix Wertek, Dagmar Walter, Blaszkiewicz Sandra, Tim Holland-Letz, Noboru Asada, Julius Graesel, Sina Staeble, Milena Block, Oezge Gizlenci, Aine M. Prendergast, Simon Haas, Daniel B. Lipka, Karsten Rippe, Benedikt Brors, Paul S. Frenette, Marieke A. G. Essers, Michael D. Milsom

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood.V128.22.1472.1472

    Web of Science

    researchmap

  • G-CSF投与時の副反応のメカニズム-交感神経支配下の好中球によるPGE2産生

    川野裕子, 福井智恵, 若橋香奈子, 石井慎一, 鈴木知秀, 佐藤真理, 佐藤真理, 浅田騰, 川野宏樹, 皆川健太郎, 定明子, 植松智, 植松智, 審良静男, 審良静男, 上出利光, 成宮周, 松井利充, 片山義雄

    日本造血細胞移植学会総会プログラム・抄録集   38th   2016

  • Distinct Contributions By Perivascular Niche Cells in Hematopoietic Stem Cell Maintenance

    Noboru Asada, Yuya Kunisaki, Takashi Nagasawa, Paul S. Frenette

    BLOOD   126 ( 23 )   2015.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 骨髄学~造血ニッチ研究から見えてきた形態学から分子基盤まで~1.骨代謝と造血環境

    淺田騰

    血液フロンティア   25 ( 3 )   313 - 320   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • The 2014 Incentive Award of the Okayama Medical Association in General Medical Science (2014 Yuuki Prize)

    Asada Noboru

    Okayama Igakkai Zasshi (Journal of Okayama Medical Association)   127 ( 3 )   175 - 178   2015

     More details

    Language:Japanese   Publisher:Okayama Medical Association  

    CiNii Article

    researchmap

  • Neutrophils Modulate Osteoblastic Niche for Hematopoietic Progenitors Via Prostaglandin E2 Production Triggered By Sympathetic Nervous System

    Yuko Kawano, Chie Fukui, Kanako Wakahashi, Shinichi Ishii, Tomohide Suzuki, Mari Sato, Noboru Asada, Hiroki Kawano, Kentaro Minagawa, Akiko Sada, Satoshi Uematsu, Shizuo Akira, Toshimitsu Uede, Shuh Narumiya, Toshimitsu Matsui, Yoshio Katayama

    BLOOD   124 ( 21 )   2014.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 骨細胞による造血制御 Invited

    浅田騰, Katayama Yoshio

    炎症と免疫   22 ( 5 )   16 - 21   2014.9

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

    researchmap

  • 血液型未確定患者のO型赤血球輸血状況

    浅野尚美, 小郷博昭, 池田亮, 山川美和, 淺田騰, 藤井敬子, 藤井伸治

    日本輸血細胞治療学会誌   60 ( 2 )   306   2014.4

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 健常人ドナー末梢血幹細胞採取時におけるクエン酸中毒発現と電解質異常について

    藤井敬子, 淺田騰, 池田亮, 浅野尚美, 小郷博昭, 藤井伸治

    日本輸血細胞治療学会誌   60 ( 2 )   405   2014.4

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • DETECTION AND KINETICS OF DONOR-DERIVED ANTI-JRA IN AN UNRELATED BONE MARROW TRANSPLANTATION RECIPIENT: A CASE REPORT

    Ikeda Toru, Ogo Hiroaki, Asano Naomi, Asada Noboru, Fujii Keiko, Fujii Nobuharu

    JJTC   60 ( 3 )   483 - 487   2014

     More details

    Language:Japanese   Publisher:The Japan Society of Transfusion Medicine and Cell Therapy  

    Jra is a frequently detected red blood cell antigen known as antigen 901005 according to the ISBT nomenclature. The frequency of Jr (a-) is 0.065% among the Japanese population. We herein report a case of a bone marrow transplantation (BMT) recipient in whom donor-derived anti-Jra was detected on day 15 after BMT. The recipient, a male patient in his fifties, had chronic myeloid leukemia in the second chronic phase after a lymphoid blast crisis. He was group A, D+, and Jr (a+) and had no other irregular antibodies. The donor, a female patient in her forties, was group A, D+, Jr (a-) and had anti-Jr (a) antibodies. A total of 6 units of randomly selected red cell concentrate (RCC) was transfused on days 9, 11, and 14 after BMT. The direct globulin test of the recipient was negative before transplantation; however, it changed to positive on day 12 after transplantation. The irregular antibody test result subsequently changed to positive, and anti-Jra was detected on day 15. Based on this result, we used Jr (a-) RCC for the next 16 units of RCC transfusion. Clinically, there were no hemolytic adverse effects. His direct globulin test and irregular antibody test became negative on days 39 and 53, respectively. Although the clinical importance of irregular antibodies in BMT donors remains unclear, establishment of guidelines for blood product selection might be useful when BMT is planned from a donor with irregular antibodies.

    DOI: 10.3925/jjtc.60.483

    CiNii Article

    researchmap

  • 血液型未確定患者へのO型赤血球輸血

    浅野尚美, 小郷博昭, 池田亮, 狩山由貴, 山川美和, 熊本貴子, 淺田騰, 藤井敬子, 藤井伸治, 岩月啓氏

    日本輸血細胞治療学会誌   59 ( 6 )   864   2013.12

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 健常人ドナー末梢血幹細胞採取時における副作用,電解質異常について

    藤井敬子, 淺田騰, 藤原英晃, 山川美和, 熊本貴子, 狩山由貴, 池田亮, 浅野尚美, 小郷博昭, 藤井伸治, 岩月啓氏

    日本輸血細胞治療学会誌   59 ( 6 )   865 - 865   2013.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    J-GLOBAL

    researchmap

  • alpha SMA plus Macrophages Skewed Fro Hematopoietic Stem Cells By Vitamin D3 Initiate Myelofibrosis and Subsequent Osteosclerosis

    Kanako Wakahashi, Kentaro Minagawa, Noboru Asada, Yuko Kawano, Mari Sato, Hiroki Kawano, Akiko Sada, Shigeaki Kato, Kotaro Shide, Kazuya Shimoda, Toshimitsu Matsui, Yoshio Katayama

    BLOOD   122 ( 21 )   2013.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    DOI: 10.1182/blood.V122.21.340.340

    Web of Science

    researchmap

  • 造血幹細胞ニッチ研究の進展

    淺田騰

    月刊血液内科   67 ( 2 )   264 - 272   2013.8

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Progress of hematopoietic stem cell niche research

    淺田 騰

    血液内科   67 ( 2 )   264 - 272   2013.8

     More details

    Language:Japanese   Publisher:科学評論社  

    CiNii Article

    CiNii Books

    researchmap

  • 血液センターとの連携により速やかに不規則抗体同定ができた稀な血液型2症例

    小郷博昭, 浅野尚美, 池田亮, 狩山由貴, 山川美和, 森繰代, 淺田騰, 藤井敬子, 藤井伸治, 岩月啓氏, 杉原珠子, 柿本真木子, 大熊重則

    日本輸血細胞治療学会誌   59 ( 1 )   88   2013.3

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 新しい全自動型血液成分分離装置Spectra Optiaを用いた末梢血幹細胞採取Cobe Spectraと比較して

    藤井敬子, 淺田騰, 西森久和, 山川美和, 森繰代, 狩山由貴, 池田亮, 浅野尚美, 小郷博昭, 藤井伸治, 岩月啓氏

    日本輸血細胞治療学会誌   59 ( 1 )   91 - 804   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    Spectra Optiaは、COBE Spectraに代わる次世代機であり、自動インターフェイス管理(AIM)システムを採用し全自動的にアフェレーシスを行うことができる。主に臨床使用経験が積まれていた欧州に対し、わが国では2011年7月に認可され今後の使用実績が期待される。今回、末梢血幹細胞採取におけるSpectra Optia(Optia)とCOBE Spectra(COBE)の比較を目的として、当院におけるOptia導入前後での末梢血幹細胞採取73件について、機器別採取結果を後方視的に検討した。採取回数はOptia群24回(自家15回、同種9回)、COBE群49回(自家36回、同種13回)、処理血液量は自家で患者体重(kg)当たり150ml、同種はドナー体重(kg)当たり200mlとした。単核球回収率は両機種間で有意差はなかったが、採取産物容量、赤血球混入量はOptia群で有意に少なかった。また同種のみで比較した場合、Optia群では採取産物中の血小板混入数が有意に少なかった。副作用面でも重篤なものはなく、血漿成分が過剰に採取されない簡便な全自動型血液成分分離装置としてOptiaは期待できるものと考えられた。(著者抄録)

    J-GLOBAL

    researchmap

  • ハプロフル移植を施行した全身性Bacillus cereus多発膿瘍を合併した急性骨髄単球性白血病の一例

    長谷川詠子, 佐伯恭昌, 黒井大雅, 淺野豪, 松岡賢市, 近藤英生, 淺田騰, 藤井敬子, 藤井伸治, 前田嘉信, 品川克至, 谷本光音

    日本造血細胞移植学会総会プログラム・抄録集   35th   275   2013.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Prostaglandin E2 Regulates Osteoblastic Niche Selectively for Hematopoietic Progenitors through Induction of Osteopontin via EP4 Receptor

    Yuko Kawano, Mari Sato, Noboru Asada, Chie Fukui, Kanako Wakahashi, Hiroki Kawano, Kentaro Minagawa, Akiko Sada, Satoshi Uematsu, Shizuo Akira, Toshimitsu Uede, Shuh Narumiya, Toshimitsu Matsui, Yoshio Katayama

    JOURNAL OF BONE AND MINERAL RESEARCH   28   2013.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • RETROSPECTIVE ANALYSIS OF PERIPHERAL BLOOD STEM CELL COLLECTION WITH Spectra Optia&reg;, A NOVEL, AUTOMATIC INTERFACE-CONTROLLED APHERESIS SYSTEM: COMPARISON WITH COBE Spectra&reg;

    Fujii Keiko, Fujii Nobuharu, Asada Noboru, Nishimori Hisakazu, Kariyama Yuki, Ikeda Toru, Asano Naomi, Ogo Hiroaki, Iwatsuki Keiji

    JJTC   59 ( 6 )   799 - 804   2013

     More details

    Language:Japanese   Publisher:The Japan Society of Transfusion Medicine and Cell Therapy  

    G-CSF-mobilized peripheral blood stem cells (PBSCs) are frequently used for autologous and allogeneic hematopoietic cell transplantation. Although the COBE Spectra&lt;sup&gt;&amp;reg;&lt;/sup&gt; Apheresis system has been commonly used, Spectra Optia&lt;sup&gt;&amp;reg;&lt;/sup&gt;, a novel automatic interface-controlled apheresis system, became available at Okayama University Hospital in July 2011. We retrospectively analyzed a total of 73 cases of apheresis, 49 performed with the COBE system and 24 with the Optia system, for 51 autologous and 22 allogeneic PBSC samples collected between January 2011 and June 2012. For autologous PBSCs, total product volume and RBC contamination of products were significantly lower in the Optia group than in the Spectra group. For allogeneic PBSCs, total WBC counts and platelet contamination, as well as total product volume and RBC contamination, were lower in the Optia group than in the Spectra group, despite MNC collection efficacy and CD34&lt;sup&gt;+&lt;/sup&gt; cell numbers being similar in both groups for autologous and allogeneic PBSCs. Automatic apheresis with the Spectra Optia system is patient- and user-friendly, and has a similar collection efficacy to that of the COBE Spectra system.&lt;br&gt;

    DOI: 10.3925/jjtc.59.799

    CiNii Article

    researchmap

  • 新しい全自動型血液成分分離装置Spectra Optiaを用いた末梢血幹細胞採取‐COBE Spectraと比較して‐

    藤井敬子, 藤井伸治, 淺田騰, 西森久和, 狩山由貴, 池田亮, 浅野尚美, 小郷博昭, 岩月啓氏

    日本輸血細胞治療学会誌   59 ( 6 )   799-804 (J-STAGE) - 804   2013

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    Spectra Optiaは、COBE Spectraに代わる次世代機であり、自動インターフェイス管理(AIM)システムを採用し全自動的にアフェレーシスを行うことができる。主に臨床使用経験が積まれていた欧州に対し、わが国では2011年7月に認可され今後の使用実績が期待される。今回、末梢血幹細胞採取におけるSpectra Optia(Optia)とCOBE Spectra(COBE)の比較を目的として、当院におけるOptia導入前後での末梢血幹細胞採取73件について、機器別採取結果を後方視的に検討した。採取回数はOptia群24回(自家15回、同種9回)、COBE群49回(自家36回、同種13回)、処理血液量は自家で患者体重(kg)当たり150ml、同種はドナー体重(kg)当たり200mlとした。単核球回収率は両機種間で有意差はなかったが、採取産物容量、赤血球混入量はOptia群で有意に少なかった。また同種のみで比較した場合、Optia群では採取産物中の血小板混入数が有意に少なかった。副作用面でも重篤なものはなく、血漿成分が過剰に採取されない簡便な全自動型血液成分分離装置としてOptiaは期待できるものと考えられた。(著者抄録)

    DOI: 10.3925/jjtc.59.799

    J-GLOBAL

    researchmap

  • 当院同種造血幹細胞移植症例におけるDisease risk indexの有用性の検討

    浅野豪, 近藤英生, 佐伯恭昌, 長谷川詠子, 黒井大雅, 西森久和, 松岡賢市, 浅田騰, 藤井敬子, 藤井伸治, 藤井伸治, 前田嘉信, 品川克至, 谷本光音

    日本造血細胞移植学会総会プログラム・抄録集   35th   2013

  • 細胞療法のための院内細胞採取・処理・保管に関する全国調査

    藤井敬子, 西森久和, 淺田騰, 藤井伸治, 山口麻由美, 池田亮, 浅野尚美, 小郷博昭, 岩月啓氏, 池田和真, 田中朝志, 佐川公矯, 大戸斉, 高橋孝喜

    日本造血細胞移植学会総会プログラム・抄録集   34th   241   2012.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 同種移植後のサイトメガロウイルス抗原血症が急性骨髄性白血病の再発に及ぼす影響

    吉田将平, 近藤英生, 浅野豪, 廻勇輔, 吉岡尚徳, 西之原正昭, 藤原英晃, 岡本幸代, 淺田騰, 西森久和, 藤井敬子, 松岡賢市, 藤井伸治, 前田嘉信, 品川克至, 谷本光音

    日本造血細胞移植学会総会プログラム・抄録集   34th   208   2012.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 中枢神経原発悪性リンパ腫に対する自己末梢血幹細胞移植併用大量化学療法

    近藤英生, 廻勇輔, 浅野豪, 吉岡尚徳, 松岡賢市, 淺田騰, 藤井敬子, 藤井伸治, 黒住和彦, 市川智継, 前田嘉信, 品川克至, 谷本光音

    日本造血細胞移植学会総会プログラム・抄録集   34th   258   2012.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Osteocytes Embedded Inside Bone Are Essential for G-CSF-Induced Hematopoietic Stem/Progenitor Mobilization

    Noboru Asada, Yoshio Katayama, Mari Sato, Kentaro Minagawa, Kanako Wakahashi, Hiroki Kawano, Yuko Kawano, Akiko Sada, Kyoji Ikeda, Toshimitsu Matsui, Mitsune Tanimoto

    BLOOD   118 ( 21 )   327 - 328   2011.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    DOI: 10.1182/blood.V118.21.721.721

    Web of Science

    researchmap

  • 血液内科領域の移植医療と再生医療―診療と研究における最近の動向 造血幹細胞動員の基礎と臨床:最近の話題

    淺田騰, 片山義雄

    月刊血液内科   63 ( 3 )   326 - 331   2011.9

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Recent advances in hematopoietic stem cell mobilization

    淺田 騰, 片山 義雄

    血液内科   63 ( 3 )   326 - 331   2011.9

     More details

    Language:Japanese   Publisher:科学評論社  

    CiNii Article

    CiNii Books

    researchmap

  • A NEW ALTERNATIVE STRATEGY FOR STAGE I IMATINIB-SENSITIVE TESTICULAR SEMINOMA; LESSONS FROM A CASE WITH PH plus ALL

    Atsuo Okamura, Kanako Wakahashi, Shinichi Ishii, Hiroki Kawano, Yuriko Kawamori, Noboru Asada, Shinichiro Nishikawa, Kentaro Minagawa, Manabu Shimoyama, Yoshio Katayama, Katsuya Yamamoto, Toshimitsu Matsui

    ANNALS OF ONCOLOGY   21   37 - 38   2010.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:OXFORD UNIV PRESS  

    Web of Science

    researchmap

  • フィラデルフイア染色体陽性急性リンパ性白血病合併例から学ぶ,限局期精巣セミノーマに対するイマチニブを用いた新たな治療戦略

    岡村篤夫, 若橋香奈子, 石井慎一, 川野宏樹, 川森有里子, 淺田騰, 西川真一郎, 皆川健太郎, 下山学, 片山義雄, 山本克也, 松井利充

    日本臨床腫瘍学会学術集会プログラム・抄録集   8th   273   2010

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 急性GVHD予防薬ミコフェノール酸モフェチル(MMF)至適投与法の確立に関する研究(第4報)

    岡村篤夫, 若橋香奈子, 川野宏樹, 川野裕子, 川森有里子, 淺田騰, 竹腰久容, 中田登紀江, 西川真一郎, 皆川健太郎, 定明子, 山本克也, 下山学, 片山義雄, 松井利充

    日本造血細胞移植学会総会プログラム・抄録集   32nd   230   2010

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 当科における同種骨髄非破壊的移植(RIST)の治療成績

    浅田騰, 小林孝一郎, 門久幸代, 近藤正太郎, 遠西大輔, 久保西四郎, 前田嘉信, 新谷勝美, 品川克至, 池田和真, 谷本光音

    日本臨床腫瘍学会学術集会プログラム・抄録集   6th   2008

  • 治療抵抗性進行期低悪性度リンパ腫に対する骨髄非破壊的同種造血幹細胞移植

    久保西四郎, 品川克至, 浅田騰, 遠西大輔, 門久幸代, 近藤正太郎, 前田嘉信, 新谷勝美, 池田和真, 谷本光音

    臨床血液   49 ( 9 )   2008

  • Primary amyloidosis associated with IgD-λ M-proteinemia

    KIMURA Shunichi, IWATSUKA Ryota, AOKI Takatoshi, ODAWARA Jun, ASADA Noboru, YAMAKURA Masayuki, TAKEUCHI Masami, MATSUE Kosei

    The Japanese journal of clinical hematology   48 ( 12 )   1555-1558,HYOSHI - 1558   2007.12

  • 当院で経験した骨髄を主病変とするCD5陽性DLBCL4症例の検討(IVLとの異同)

    青木孝友, 小田原淳, 淺田騰, 木村俊一, 山倉昌之, 竹内正美, 末永孝生

    日本リンパ網内系学会会誌   47   114   2007.5

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 過去8年間の当院における血管内リンパ腫11例の臨床病理学的検討

    木村俊一, 末永孝生, 竹内正美, 山倉昌之, 淺田騰, 青木孝友, 小田原淳

    日本リンパ網内系学会会誌   47   113   2007.5

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • ホストファクターと血清ガラクトマンナン値および治療開始時期に基づいた侵襲性肺アスペルギルス症の予後評価

    瓜生英尚, 淺田騰, 木村俊一, 末永考生

    感染症学雑誌   80 ( 6 )   785   2006.11

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • ミカファンギン投与による侵襲性トリコスポロン症のbreakthroughを発症した4症例の検討

    淺田騰, 瓜生英尚, 末永考生

    感染症学雑誌   80 ( 6 )   785 - 786   2006.11

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Reply to Rodríguez-Tudela and Cuenca-Estrella [2]

    Kosei Matsue, Noboru Asada, Takashi Sugita

    Clinical Infectious Diseases   43 ( 10 )   1370 - 1371   2006.11

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)   Publisher:University of Chicago Press  

    DOI: 10.1086/508666

    Scopus

    researchmap

  • 当院の2年間における血清中アスペルギルスガラクトマンナンの解析

    瓜生 英尚, 小関 美保子, 浅田 騰, 竹内 正美, 末永 孝生

    The Japanese journal of antibiotics   59 ( 5 )   413 - 414   2006.10

     More details

  • 胃原発悪性リンパ腫57例に対する胃温存化学療法の治療成績 亀田総合病院における経験から

    小関美保子, 瓜生英尚, 淺田騰, 竹内正美, 草薙洋, 小久保武, 末永孝生

    臨床血液   47 ( 9 )   1122   2006.9

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 患者リスクと血清ガラクトマンナン値および治療開始時期に基づいた侵襲性肺アスペルギルス症の予後評価

    瓜生英尚, 小関美保子, 淺田騰, 木村俊一, 竹内正美, 末永孝生

    臨床血液   47 ( 9 )   1145   2006.9

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

▼display all

Presentations

  • 臍帯血移植後にHTLV-1感染T細胞の多クローン性増殖を伴って発症した肺合併症に対し抗CCR4抗体が著効した1例

    松原 千哲, 松岡 賢市, 近藤 歌穂, 藤原 加奈子, 寺尾 俊紀, 植田 裕子, 松村 彰文, 守山 喬史, 村上 裕之, 近藤 匠, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 藤井 伸治, 前田 嘉信

    臨床血液  2023.6  (一社)日本血液学会-東京事務局

     More details

    Event date: 2023.6

    Language:Japanese  

    researchmap

  • 高齢者のセザリー症候群に対してインターフェロンγが奏功した1例

    澤井 希望, 三宅 智子, 徳田 真優, 佐藤 志帆, 立花 宏太, 杉本 佐江子, 川上 佳夫, 森実 真, 萩谷 英大, 淺田 騰

    日本皮膚科学会雑誌  2023.5  (公社)日本皮膚科学会

     More details

    Event date: 2023.5

    Language:Japanese  

    researchmap

  • 当院における再発難治性びまん性大細胞型B細胞性リンパ腫に対するtisagenlecleucelの治療成績

    北村 亘, 藤井 伸治, 鴨井 千尋, 阿部 将也, 住居 優一, 浦田 知宏, 谷 勝真, 高木 尚江, 山本 晃, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本輸血細胞治療学会誌  2023.4  (一社)日本輸血・細胞治療学会

     More details

    Event date: 2023.4

    Language:Japanese  

    researchmap

  • Tisagenlecleucel投与後のステロイド抵抗性CRSに対し、cyclophosphamide投与を行い改善が得られた1例

    守山 喬史, 藤原 英晃, 村上 裕之, 松村 彰文, 大山 矩史, 淺田 騰, 西森 久和, 藤井 敬子, 藤井 伸治, 遠西 大輔, 末次 慶收, 松岡 賢市, 前田 嘉信

    臨床血液  2022.6  (一社)日本血液学会-東京事務局

     More details

    Event date: 2022.6

    Language:Japanese  

    researchmap

  • Tisagenlecleucel投与後のステロイド抵抗性CRSに対し、cyclophosphamide投与を行い改善が得られた1例

    守山 喬史, 藤原 英晃, 村上 裕之, 松村 彰文, 大山 矩史, 淺田 騰, 西森 久和, 藤井 敬子, 藤井 伸治, 遠西 大輔, 末次 慶收, 松岡 賢市, 前田 嘉信

    臨床血液  2022.6  (一社)日本血液学会-東京事務局

     More details

    Event date: 2022.6

    Language:Japanese  

    researchmap

  • Gilteritinib maintenance therapy post-SCT improves the prognosis of patients with R/R FLT3mut AML

    寺尾俊紀, 松岡賢市, 植田裕子, 松村彰文, 松原千哲, 近藤歌穂, 近藤匠, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集  2022 

     More details

    Event date: 2022

    researchmap

  • Modification of post-transplant cyclophosphamide and tacrolimus in haploidentical transplantation

    寺尾俊紀, 松岡賢市, 近藤匠, 高須賀裕樹, 鴨井千尋, 植田裕子, 松村彰文, 松原千哲, 近藤歌穂, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集  2022 

     More details

    Event date: 2022

    researchmap

  • Analysis of cryopreserved unrelated donor bone marrow transplantation under the COVID-19 pandemic

    松村彰文, 藤原英晃, 植田裕子, 守山喬史, 村上裕之, 住井優一, 浦田知宏, 木村真衣子, 近藤匠, 浅田騰, 遠西大輔, 西森久和, 松岡賢市, 藤井敬子, 藤井伸治, 鴨井千尋, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集  2022 

     More details

    Event date: 2022

    researchmap

  • Influence of oral microbiota on graft-versus-host disease and its role as a therapeutic target

    神原由依, 藤原英晃, 山本晃, 國廣まり, 大山矩史, 近藤匠, 淺田騰, 遠西大輔, 西森久和, 藤井伸治, 藤井敬子, 松岡賢市, 前田嘉信, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集  2022 

     More details

    Event date: 2022

    researchmap

  • Open-label, randomized study to calcium drink for prevention of citrate toxicity of PBSC donor

    藤井敬子, 藤井敬子, 藤井伸治, 藤井伸治, 三橋利晴, 住居優一, 住居優一, 谷勝真, 谷勝真, 浦田知宏, 浦田知宏, 木村真衣子, 木村真衣子, 近藤匠, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 大塚文男, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集  2022 

     More details

    Event date: 2022

    researchmap

  • Clinical significance of gynecological examinations in LTFU

    鴨井千尋, 鴨井千尋, 藤井伸治, 藤井伸治, 松岡敬典, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井敬子, 松岡賢市, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集  2022 

     More details

    Event date: 2022

    researchmap

  • Analysis of the efficacy of the tablet-based patient orientation for CAR-T therapy

    海内千春, 山成洋子, 山本佳代, 高木尚江, 淺田騰, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集  2022 

     More details

    Event date: 2022

    researchmap

  • Development of a new collection procedure for granulocyte apheresis

    藤井敬子, 藤井敬子, 藤井伸治, 藤井伸治, 住居優一, 住居優一, 浦田知宏, 浦田知宏, 木村真衣子, 木村真衣子, 近藤匠, 近藤匠, 藤原英晃, 淺田騰, 遠西大輔, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集  2022 

     More details

    Event date: 2022

    researchmap

  • Analysis of difficulties experienced by nurses in the care of patients treated with CAR T therapy

    山成洋子, 大西沙紀, 猪木華絵, 加賀城愛未, 山本佳代, 小倉妥子, 海内千春, 淺田騰, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集  2022 

     More details

    Event date: 2022

    researchmap

  • High-dose steroids within 7 days after diagnosis may improve prognosis of NIPC post HSCT(和訳中)

    神原 由依, 藤井 伸治, 碓井 喜明, 山本 晃, 肥後 寿夫, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本血液学会学術集会  2021.9  (一社)日本血液学会

     More details

    Event date: 2021.9

    Language:English  

    researchmap

  • The effect of live attenuated vaccines after allo-HSCT for adult patients(和訳中)

    鴨井 千尋, 吉田 将平, 藤井 伸治, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本血液学会学術集会  2021.9  (一社)日本血液学会

     More details

    Event date: 2021.9

    Language:English  

    researchmap

  • Resistance mechanism to CAR-T therapy considered from pathological examination of replaced lymphoma(和訳中)

    胡中 公謹, 松村 卓郎, 酒井 康平, 富永 貴元, 淺田 騰, 高須賀 裕樹, 小林 宏紀, 高橋 徹

    日本血液学会学術集会  2021.9  (一社)日本血液学会

     More details

    Event date: 2021.9

    Language:English  

    researchmap

  • The relationship between steroid usage and the prognosis after CAR-T cell therapy in r/r DLBCL(和訳中)

    北村 亘, 淺田 騰, 大山 矩史, 村上 裕之, 高須賀 裕樹, 池内 一廣, 小林 宏紀, 福見 拓也, 木村 真衣子, 近藤 匠, 松田 真幸, 池川 俊太郎, 今中 智子, 藤原 悠紀, 浦田 真吾, 松村 卓郎, 今村 豊, 竹内 誠, 平松 靖史, 近藤 英生, 藤原 英晃, 遠西 大輔, 西森 久和, 藤井 敬子, 藤井 伸治, 上田 恭典, 松岡 賢市, 前田 嘉信

    日本血液学会学術集会  2021.9  (一社)日本血液学会

     More details

    Event date: 2021.9

    Language:English  

    researchmap

  • Prognostic impact of Day 30 WT1 after PTCY-haplo in myeloid neoplasm: A multi-center study from OHSG(和訳中)

    北村 亘, 藤井 伸治, 名和 由一郎, 杉浦 弘幸, 藤下 惠悟, 吉岡 尚徳, 藤原 悠紀, 大山 矩史, 村上 裕之, 高須賀 裕樹, 池内 一廣, 池川 俊太郎, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 木口 亨, 今井 利, 平松 靖史, 前田 嘉信

    日本血液学会学術集会  2021.9  (一社)日本血液学会

     More details

    Event date: 2021.9

    Language:English  

    researchmap

  • EBV viremia with NK/T cells as well as B cells after hematopoietic stem cell transplantation(和訳中)

    大山 矩史, 西森 久和, 村上 裕之, 高須賀 裕樹, 北村 亘, 藤原 英晃, 淺田 騰, 藤井 敬子, 藤井 伸治, 遠西 大輔, 松岡 賢市, 前田 嘉信

    日本血液学会学術集会  2021.9  (一社)日本血液学会

     More details

    Event date: 2021.9

    Language:English  

    researchmap

  • Marfan症候群に先天性第XI因子欠乏症とvon Willebrand病(VWD)を合併した患者の心臓弁膜症手術の周術期管理

    大山 矩史, 淺田 騰, 末澤 孝徳, 新谷 憲治, 廣田 真規, 池内 一廣, 北村 亘, 高須賀 裕樹, 藤原 英晃, 遠西 大輔, 西森 久和, 藤井 伸治, 松岡 賢市, 笠原 真悟, 前田 嘉信

    臨床血液  2021.6  (一社)日本血液学会-東京事務局

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • 移植後シクロホスファミドを用いた血縁者間HLA半合致移植後に最重症遅発性肝類洞閉塞症候群を合併した非定型慢性骨髄性白血病

    北村 亘, 藤井 伸治, 大西 秀樹, 高須賀 裕樹, 大山 矩史, 村上 裕之, 木村 真衣子, 近藤 匠, 松田 真幸, 池川 俊太郎, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 木口 亨, 柳井 広之, 吉野 正, 前田 嘉信

    臨床血液  2021.6  (一社)日本血液学会-東京事務局

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • 移植後シクロホスファミドを用いた血縁者間HLA半合致移植後に最重症遅発性肝類洞閉塞症候群を合併した非定型慢性骨髄性白血病

    北村 亘, 藤井 伸治, 大西 秀樹, 高須賀 裕樹, 大山 矩史, 村上 裕之, 木村 真衣子, 近藤 匠, 松田 真幸, 池川 俊太郎, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 木口 亨, 柳井 広之, 吉野 正, 前田 嘉信

    臨床血液  2021.6  (一社)日本血液学会-東京事務局

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • 長期的に赤血球輸血依存状態となった成人ドミナント型βサラセミア患者に対する根治治療としての造血幹細胞移植

    北村 亘, 藤井 伸治, 但馬 史人, 高須賀 裕樹, 大山 矩史, 村上 裕之, 木村 真衣子, 近藤 匠, 松田 真幸, 池川 俊太郎, 高木 尚江, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本輸血細胞治療学会誌  2021.5  (一社)日本輸血・細胞治療学会

     More details

    Event date: 2021.5

    Language:Japanese  

    researchmap

  • モガムリズマブ投与後に移植片対宿主病が重症化した成人T細胞白血病の3例

    横山 恵美, 赤松 由規, 山崎 修, 山本 晃, 大山 矩史, 神原 由依, 淺田 騰, 谷口 恒平, 吉野 正, 森実 真

    日本皮膚科学会雑誌  2021.5  (公社)日本皮膚科学会

     More details

    Event date: 2021.5

    Language:Japanese  

    researchmap

  • 二次感染を契機に増悪し、モガムリズマブが奏効したセザリー症候群の1例

    赤松 由規, 平井 陽至, 渡部 桃子, 中川 裕貴, 小橋 美那, 内藤 聖子, 三宅 智子, 山崎 修, 森実 真, 山本 晃, 淺田 騰

    日本皮膚科学会雑誌  2021.2  (公社)日本皮膚科学会

     More details

    Event date: 2021.2

    Language:Japanese  

    researchmap

  • Determining processing blood volume due to CD3 cells and adjusting device setting for long apheresis

    藤井敬子, 藤井敬子, 藤井伸治, 藤井伸治, 木村真衣子, 木村真衣子, 近藤匠, 近藤匠, 松田真幸, 松田真幸, 池川俊太郎, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集  2021 

     More details

    Event date: 2021

    researchmap

  • A retrospective study of the effects of Defibrotide for VOD/SOS: a single institution experience

    大山矩史, 藤井伸治, 池内一廣, 北村亘, 高須賀裕樹, 鴨井千尋, 淺田騰, 西森久和, 藤井敬子, 藤原英晃, 遠西大輔, 松岡賢市, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集  2021 

     More details

    Event date: 2021

    researchmap

  • EBV viremia with NK/T cells as well as B cells after hematopoietic stem cell transplantation

    大山矩史, 西森久和, 村上裕之, 高須賀裕樹, 北村亘, 藤原英晃, 淺田騰, 藤井敬子, 藤井伸治, 遠西大輔, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • High-dose steroids within 7 days after diagnosis may improve prognosis of NIPC post HSCT

    神原由依, 藤井伸治, 碓井喜明, 山本晃, 肥後寿夫, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 松岡賢市, 前田嘉信, 前田嘉信

    日本血液学会学術集会抄録(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • The relationship between steroid usage and the prognosis after CAR-T cell therapy in r/r DLBCL

    北村亘, 淺田騰, 大山矩史, 村上裕之, 高須賀裕樹, 池内一廣, 小林宏紀, 福見拓也, 木村真衣子, 近藤匠, 松田真幸, 池川俊太郎, 池川俊太郎, 今中智子, 藤原悠紀, 浦田真吾, 松村卓郎, 今村豊, 竹内誠, 平松靖史, 近藤英生, 藤原英晃, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 上田恭典, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • Prognostic impact of Day 30 WT1 after PTCY-haplo in myeloid neoplasm: A multi-center study from OHSG

    北村亘, 藤井伸治, 藤井伸治, 名和由一郎, 杉浦弘幸, 藤下惠悟, 吉岡尚徳, 藤原悠紀, 大山矩史, 村上裕之, 高須賀裕樹, 池内一廣, 池川俊太郎, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 遠西大輔, 西森久和, 藤井敬子, 松岡賢市, 木口亨, 今井利, 平松靖史, 前田嘉信

    日本血液学会学術集会抄録(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • 肝膿瘍を合併した急性骨髄性白血病の造血幹細胞移植時に顆粒球輸注が有効であった1例

    谷岡 桃子, 福見 拓也, 神原 由依, 池内 一廣, 小林 宏紀, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 伸治, 松岡 賢市, 前田 嘉信

    臨床血液  2020.10  (一社)日本血液学会-東京事務局

     More details

    Event date: 2020.10

    Language:Japanese  

    researchmap

  • 原発性マクログロブリン血症から形質転換したGerminal Center B-cellタイプのびまん性大細胞型B細胞リンパ腫の症例

    小林 宏紀, 淺田 騰, 遠西 大輔, 阿部 将也, 池田 知佳, 坂本 美彩, 江草 侑厘安, 廻 勇輔, 西森 久和, 藤井 伸治, 松岡 賢市, 佐藤 康晴, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌  2020.7  (一社)日本リンパ網内系学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 原発性マクログロブリン血症から形質転換したGerminal Center B-cellタイプのびまん性大細胞型B細胞リンパ腫の症例

    小林 宏紀, 淺田 騰, 遠西 大輔, 阿部 将也, 池田 知佳, 坂本 美彩, 江草 侑厘安, 廻 勇輔, 西森 久和, 藤井 伸治, 松岡 賢市, 佐藤 康晴, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌  2020.7  (一社)日本リンパ網内系学会

     More details

    Event date: 2020.7

    Language:Japanese  

    researchmap

  • 造血幹細胞ニッチによる造血制御 Invited

    淺田 騰

    第30回日本サイトメトリー学会 学術集会 

     More details

    Event date: 2020.5.30 - 2020.5.31

    Presentation type:Symposium, workshop panel (nominated)  

    researchmap

  • A report of two cases: resection of intestinal canal with complications associated with hematopoietic stem cell transplantation

    山本晃, 藤井伸治, 近藤喜太, 田中健大, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 松川昭博, 吉野正, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集  2020 

     More details

    Event date: 2020

    researchmap

  • B-ALL performed HLA haploidentical stem cell transplantation using post-transplant cyclophosphamide after administration of inotuzumab ozogemicin

    阿部将也, 藤井伸治, 藤井伸治, 水原健太郎, 浦田知宏, 住居優一, 藤原悠紀, 清家圭介, 三道康永, 中村真, 藤井敬子, 佐伯恭昌, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集  2020 

     More details

    Event date: 2020

    researchmap

  • Successful cord blood transplantation for refractory chronic active Epstein-Barr virus infection

    福見拓也, 藤井伸治, 神原由依, 山本晃, 阿部将也, 小林宏紀, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集  2020 

     More details

    Event date: 2020

    researchmap

  • Adjusting processed blood volume of apheresis individully based on pre CD34+cell and collection efficiency can be best for both donor and recipient

    藤井敬子, 藤井敬子, 藤井伸治, 藤井伸治, 池川俊太郎, 池川俊太郎, 杉浦弘幸, 杉浦弘幸, 清家圭介, 清家圭介, 三道康永, 三道康永, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集  2020 

     More details

    Event date: 2020

    researchmap

  • PTCyは,移植前ニボルマブ治療を受けた患者のTreg恒常性を回復させ,急性GVHDを抑制する

    池川俊太郎, 松岡賢市, 水原健太郎, 福見拓也, 小林宏紀, 住居優一, 近藤匠, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 藤澤佑香, 今井利, 前田嘉信

    日本血液学会学術集会抄録(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 当院での中枢神経浸潤を有するリンパ腫に対してチオテパを用いた自家移植症例の検討

    小林宏紀, 藤井伸治, 近藤英生, 藤井敬子, 池川俊太郎, 木村真衣子, 近藤匠, 松田真幸, 阿部将也, 池内一廣, 神原由依, 福見拓也, 山本晃, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • 抗GPVI抗体による血小板凝集能異常を合併したTAFRO症候群の一例

    小村綾, 山本晃, 西森久和, 白井俊光, 神原由依, 福見拓也, 浦田知宏, 廻勇輔, 淺田騰, 遠西大輔, 松岡賢市, 藤井伸治, 高野勝弘, 井上克枝, 前田嘉信

    日本血液学会学術集会抄録(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • チサゲンレクルユーセル投与後の遷延性血球減少の2症例

    福見拓也, 藤井伸治, 藤井伸治, 神原由依, 池内一廣, 小林宏紀, 木村真衣子, 木村真衣子, 近藤匠, 近藤匠, 松田真幸, 松田真幸, 池川俊太郎, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井敬子, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)  2020 

     More details

    Event date: 2020

    researchmap

  • No Evidence for Hematopoietic Stem Cell Self-Renewal in-Vivo Following Inflammatory Challenge

    Ruzhica Bogeska, PhD, Paul Kaschutnig, PhD, Stella V Paffenholz, MSc, Julia Knoch, Jan-Philipp Mallm, PhD, Malak Fawaz, MSc, Florian Buettner, PhD, Dagmar Walter, PhD, Felix Frauhammer, MSc, Tim Holland-Letz, PhD, Noboru Asada, MD PhD, Ana-Matea Mikecin, Drazic, PhD, Marleen Buechler-Schaff, MSc, Martha Correno-Gonzalez, Melanie Ball, Sina Staeble, MSc, Julius, Gräsel, PhD, Simon Haas, PhD, Daniel B. Lipka, MD, Karsten Rippe, PhD, Benedikt Brors, PhD, Paul S. Frenette, MD, Michael A. Rieger, Marieke A, G. Essers, PhD, Michael D. Milsom, PhD

    61th American Society of Hematology Annual Meeting and Exposition 

     More details

    Event date: 2019.12.7

    researchmap

  • Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

    Isamu Sugiura, MD, Noriko Doki, MD PhD, Tomoko Hata, MD, PhD, Ryuko CHO, MD PhD, Toshiro Ito, MD, Youko Suehiro, MD PhD, Heiwa Kanamori, MD PhD, Shinichi Kako, MD, Mitsuhiro Matsuda, MD PhD, Hisayuki Yokoyama, MD PhD, Yasuhiro Taniguchi, MD, Maki Hagihara, MD PhD, Yukiyasu Ozawa, MD PhD, Shin Fujisawa, MD PhD, Nobuaki Dobashi, MD, Yoshihiro Hatta, MD, Noboru Asada, MD PhD, Kazuteru Ohashi, MD PhD, Yasushi Onishi, MD PhD, Koh Shiro, MD PhD, Satoshi Nishiwaki, MD PhD, Yoshiko Atsuta, MD PhD, Fumihiko Hayakawa, MD PhD, Shigeki Ohtake, MD PhD, Yasushi Miyazaki, MD PhD

    61th American Society of Hematology Annual Meeting and Exposition 

     More details

    Event date: 2019.12.7

    researchmap

  • Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

    Isamu Sugiura, Noriko Doki, Tomoko Hata, Ryuko Cho, Toshiro Ito, Youko Suehiro, Heiwa Kanamori, Shinichi Kako, Mitsuhiro Matsuda, Hisayuki Yokoyama, Yasuhiro Taniguchi, Maki Hagihara, Yukiyasu Ozawa, Shin Fujisawa, Nobuaki Dobashi, Yoshihiro Hatta, Noboru Asada, Kazuteru Ohashi, Yasushi Onishi, Koh Shiro, Satoshi Nishiwaki, Yoshiko Atsuta, Fumihiko Hayakawa, Shigeki Ohtake, Yasushi Miyazaki

    BLOOD  2019.11  AMER SOC HEMATOLOGY

     More details

    Event date: 2019.11

    Language:English  

    0

    researchmap

  • No Evidence for Hematopoietic Stem Cell Self-Renewal in-Vivo Following Inflammatory Challenge

    Ruzhica Bogeska, Paul Kaschutnig, Stella V. Paffenholz, Julia Knoch, Jan-Philipp Mallm, Malak Fawaz, Florian Buettner, Dagmar Walter, Felix Frauhammer, Tim Holland-Letz, Noboru Asada, Ana-Matea Mikecin Drazic, Marleen Buechler-Schaff, Martha Correno-Gonzalez, Melanie Ball, Sina Staeble, Julius Grasel, Simon Haas, Daniel B. Lipka, Karsten Rippe, Benedikt Brors, Paul S. Frenette, Michael A. Rieger, Marieke A. G. Essers, Michael D. Milsom

    BLOOD  2019.11  AMER SOC HEMATOLOGY

     More details

    Event date: 2019.11

    Language:English  

    0

    researchmap

  • 初発Ph+ALLに対するダサチニブ併用二段化学療法の臨床第II相試験JALSG Ph+ALL213

    杉浦 勇, 土岐 典子, 波多 智子, 趙 龍桓, 伊藤 俊朗, 末廣 陽子, 金森 平和, 賀古 真一, 松田 光弘, 横山 寿, 谷口 康, 萩原 真, 小澤 幸, 藤澤, 土橋 史, 八田 善, 淺田, 大橋 一輝, 大西, 康, 西脇 聡, 熱田 由, 早川 文, 大竹 茂, 宮崎 泰司

    第81回日本血液学会学術集会 

     More details

    Event date: 2019.10.11

    researchmap

  • モガムリズマブ投与後の移植後中枢神経再発にレナリドミド併用DLI療法が奏功した成人T細胞白血病・リンパ腫

    藤原 悠紀, 松岡 賢市, 三道 康永, 住居 優一, 阿部 将也, 水原 健太郎, 浦田 知宏, 清家 圭介, 中村 真, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 藤井 伸治, 前田 嘉信

    第81回日本血液学会学術集会 

     More details

    Event date: 2019.10.11

    researchmap

  • 急性骨髄性白血病に対する臍帯血移植後に発症しバンコマイシン髄注と顆粒球輸注が有効であったEnterococcus faecium髄膜炎の1例

    上田 弥生, 水原 健太郎, 松岡 賢市, 阿部 将也, 浦田 知宏, 神原 由依, 住居 優一, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 伸治, 前田 嘉信

    臨床血液  2019.5  (一社)日本血液学会-東京事務局

     More details

    Event date: 2019.5

    Language:Japanese  

    researchmap

  • Cyclophosphamide(CY)が奏効した難治性TAFRO症候群の一例

    浦田 知宏, 遠西 大輔, 水原 健太郎, 阿部 将也, 住居 優一, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 西森 久和, 藤井 伸治, 藤井 敬子, 佐藤 康晴, 松岡 賢市, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌  2019.5  (一社)日本リンパ網内系学会

     More details

    Event date: 2019.5

    Language:Japanese  

    researchmap

  • TFL Deletion Induces Incredible CXCL13 Secretion and Cachexia in Vavp-Bcl2 Transgenic Mice

    Kentaro Minagawa, Kanako Wakahashi, Fukui Chie, Shinichiro Nishikawa, Noboru Asada, Yuko Kawano, Hiroki Kawano, Tomohide Suzuki, Shinichi Ishii, Yoshio Katayama, Toshimitsu Matsui

    60th American Society of Hematology Annual Meeting and Exposition 

     More details

    Event date: 2018.12 - 2018.12.4

    researchmap

  • Prolonged Cytopenia after CAR-T Cell Therapy Is Associated with BM Niche Disruption and a Sustained Inflammation in the BM

    Wataru Kitamura, Noboru Asada, Yusuke Naoi, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    Transplantation & Cellular Therapy Meetings of ASCTC and CIBMR  2023.2.15 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  • 末梢神経系による造血調節と腫瘍制御

    淺田 騰

    第84回日本血液学会学術集会  2022.10.16 

     More details

    Language:Japanese   Presentation type:Oral presentation (invited, special)  

    researchmap

  • Severe cervical complications after CAR-T therapy in patients with relapsed or refractory DLBCL

    Hiroyuki Murakami, Noboru Asada, Takashi Moriyama, Chisato Matsubara, Akifumi Matsumura, Hiroko Ueda, Maiko Kimura, Takumi Kondo, Tomohiro Urata, Yuichi Sumii, Hideaki Fujiwara, Hisakazu Nishimori, Daisuke Ennishi, Keiko Fuji, Nobuharu Fuji, Kenichi Matsuoka, Yoshinobu Maeda

    2022.10 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • Clinical impact of cell-of-origin and DHIT-signature of DLBCL in Japan: OHSG 1K-DLBCL project

    Tomohiro Urata, Daisuke Ennishi, Kazutaka Sunami, Toshi Imai, Yuichiro Nawa, Yasushi Hiramatsu, Kazuhiko Yamamoto, Soichiro Fujii, Isao Yoshida, Tomofumi Yano, Yusuke Naoi, Kazuhiro Ikeuchi, Hiroki Kobayashi, Katsuma Tani, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Kenichi Matsuoka, Yasuharu Sato, Tadashi Yoshino, Yoshinobu Maeda

    2022.10 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • Double remission of CLL and AML with venetoclax followed by haploidentical stem cell transplantation

    Takashi Moriyama, Kenichi Matsuoka, Chisato Matsubara, Akifumi Matsumura, Hiroko Ueda, Hiroyuki Murakami, Maiko Kimura, Takumi Kondo, Tomohiro Urata, Yuichi Sumii, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Daisuke Ennishi, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    2022.10 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • Aroma component of cypress (hinoki) exhibits anti-tumor activity against T-cell malignancies

    Masaya Abe, Noboru Asada, Chie Fukui, Maiko Kimura, Daisuke Yamada, Wataru Kitamura, Masayuki Matsuda, Takeshi Takarada, Yoshinobu Maeda

    2022.10 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • Neural regulation of normal and malignant hematopoiesis in bone marrow microenvironment

    Noboru Asada

    NEURO2022  2022.7.2 

     More details

    Language:English   Presentation type:Symposium, workshop panel (public)  

    researchmap

  • ALTERATION OF BONE MARROW NICHE BY ALLOGENEIC IMMUNE REACTION AFTER HSCT

    Maiko Kimura, Noboru Asada, Masayuki Matsuda, Masaya Abe, Wataru Kitamura, Ken-ichi Matsuoka, Hideaki Fujiwara, Mitsuaki Ono, Wang Ziyi, Tomoyuki Mukai, Yoshitaka Morita, Yoshinobu Maeda

    EHA2022  2022.6.10 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  • 造血幹細胞移植後の同種免疫反応による骨髄ニッチの変容

    木村真衣子, 淺田 騰, 松田真幸, 阿部将也, 大野充昭, 向井知之, 森田吉孝, 前田嘉信

    第43回日本造血幹細胞移植学会総会  2021 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • Tisagenlecleucelによる再発・難治性DLBCLの治療成績

    北村亘, 淺田 騰, 藤原英晃, 藤井伸治, 池内一廣, 高須賀裕樹, 大山矩史, 小林宏紀, 福見拓也, 佐伯恭昌, 廻勇輔, 遠西大輔, 西森久和, 藤井敬子, 松岡賢市, 松村卓郎, 今村豊, 前田嘉信

    第43回日本造血幹細胞移植学会総会  2021 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • CAR-T療法でのリンパ球アフェレーシス 末梢血CD3+数に基づく処理量決定とロングアフェレーシスでの工夫

    藤井敬子, 藤井伸治, 木村真衣子, 近藤匠, 松田真幸, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 松岡賢市, 前田嘉信

    第43回日本造血幹細胞移植学会総会  2021 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • 前縦隔に発生し,急速に増大傾向をみとめたMZL+DLBCLの1例

    蒔田郁人, 北村亘, 淺田 騰, 藤原英晃, 西森久和, 藤井伸治, 松岡賢市, 前田嘉信, 柴田嶺, 吉野正

    第123回日本内科学会中国地方会  2020 

     More details

  • 乳腺病変を有する成人T細胞性白血病/リンパ腫の1例

    小川洋平, 小林宏紀, 淺田 騰, 阿部将也, 廻勇輔, 遠西大輔, 西森久和, 藤井伸治, 松岡賢市, 前田嘉信

    第121回日本内科学会中国地方会  2019.10.5 

     More details

  • 免疫チェックポイント阻害薬治療後の同種造血幹細胞移植後に非典型的な免疫反応を呈したホジキンリンパ腫の1例

    師岡和輝, 西森久和, 水原健太郎, 廻勇輔, 淺田 騰, 遠西大輔, 松岡賢市, 藤井伸治, 前田嘉信

    第121回日本内科学会中国地方会  2019.10.5 

     More details

  • 当施設にて診断されたIgG4産生辺縁帯リンパ腫の治療成績に関する後方視的解析

    住居 優一, 淺田 騰, 佐藤 康晴, 藤原 悠紀, 阿部 将也, 水原 健太郎, 浦田 知宏, 佐伯 恭昌, 廻 勇輔, 遠西 大輔, 西森 久和, 松岡 賢市, 藤井 伸治, 吉本 祐介, 牧田 雅典, 今城 健二, 吉野 正, 前田 嘉信

    第81回日本血液学会学術集会  2019.10 

     More details

  • Cyclophosphamide (CY) が奏効した難治性TAFRO症候群の一例

    浦田知宏, 遠西大輔, 水原健太郎, 阿部将也, 住居優一, 藤原悠紀, 佐伯恭昌, 廻勇輔, 淺田騰, 西森久和, 藤井伸治, 藤井敬子, 佐藤康晴, 松岡賢市, 吉野正, 前田嘉信

    第59回日本リンパ網内系学会総会  2019.6.29 

     More details

  • EBV陽性びまん性大細胞型B細胞リンパ腫に対する化学療法施行後に血管免疫芽球性T細胞リンパ腫を発症した1例

    渡邊真衣, 水原健太郎, 遠西大輔, 阿部将也, 住居優一, 浦田知宏, 藤原悠紀, 佐伯恭昌, 廻勇輔, 淺田騰, 西森久和, 松岡賢市, 藤井伸治, 吉野正, 前田嘉信

    第59回日本リンパ網内系学会総会  2019.6.29 

     More details

  • 肺動脈浸潤と心タンポナーデを来したホジキンリンパ腫に対してnivolumabと放射線療法併用により救命しえた1例

    松本顕, 水原健太郎, 西森久和, 佐伯恭昌, 廻勇輔, 淺田騰, 遠西大輔, 松岡賢市, 藤井伸治, 前田嘉信

    第120回日本内科学会中国地方会  2019.6.1 

     More details

  • 後腹膜原発IgG4産生extranodal marginal zone lymphomaの1例

    住居優一, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信, 佐藤康晴, 藤井伸治, 吉野正

    第120回日本内科学会中国地方会  2019.6.1 

     More details

  • 自家末梢血幹細胞採取のための高用量G-CSF投与により低酸素血症を来した1例

    近藤花織, 神原由依, 住居優一, 藤原悠紀, 佐伯恭昌, 淺田騰, 前田嘉信, 清家圭介, 三道康永, 藤井敬子

    第119回日本内科学会中国地方会  2018.11.17 

     More details

  • PD-1阻害薬使用後の自家造血幹細胞移植におけるサイトカイン放出症候群の病態解析

    碓井 喜明, 松岡 賢市, 廻 勇輔, 岩本 美紀, 三道 康永, 坂本 真衣子, 藤原 悠紀, 近藤 匠, 谷 勝真, 佐伯 恭昌, 岡本 幸代, 淺田 騰, 西森 久和, 藤井 伸治, 近藤 英生, 前田 嘉信

    第80回日本血液学会学術集会  2018.10.12 

     More details

  • 造血幹細胞移植における患者指定適合血小板輸血の有効性についての検討

    清家 圭介, 藤井 伸治, 藤井 敬子, 三道 康永, 中村 真, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 松岡 賢市, 前田 嘉信

    第80回日本血液学会学術集会  2018.10.12 

     More details

  • Functional diversity of hematopoietic stem cell niche Invited

    Noboru Asada

    2018.10.12 

     More details

    Language:English   Presentation type:Symposium, workshop panel (nominated)  

    researchmap

  • 菌状息肉症に対する同種造血幹細胞移植後にシドフォビルを投与したBKウイルスによる難治性出血性膀胱炎

    藤原 悠紀, 西森 久和, 碓井 喜明, 坂本 真衣子, 近藤 匠, 谷 勝真, 淺田 騰, 松岡 賢市, 藤井 伸治, 前田 嘉信

    第118回日本内科学会中国地方会  2018.5.19 

     More details

  • "乳房腫脹を契機に診断された Peripheral T-cell lymphoma(PTCL), with T follicular helper phenotypeの1例"

    碓井 喜明, 松岡 賢市, 坂本 麻衣子, 藤原 悠紀, 近藤 匠, 谷 勝真, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 岡本 幸代, 西森 久和, 近藤 英生, 藤井 伸治, 吉野 正, 前田 嘉信

    第57回日本血液学会中国・四国地方会  2018.3.3 

     More details

    Language:Japanese  

    researchmap

  • 同種移植後再発に対する2nd HSCTの後方視的解析;Haploidentical移植の有用性の検討

    岡本 幸代, 松岡 賢市, 坂本 真衣子, 碓井 喜明, 藤原 悠紀, 近藤 匠, 松田 真幸, 谷 勝真, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 西森 久和, 藤井 伸治, 近藤 英生, 前田 嘉信

    第40回日本造血細胞移植学会総会  2018.2.1 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • Myelin basic proteinが活動性の指標となりえた同種移植後のネララビン関連脊髄炎

    坂本真衣子, 碓井喜明, 藤原悠紀, 谷勝真, 近藤匠, 佐伯恭昌, 廻勇輔, 岡本幸代, 淺田騰, 西森久和, 松岡賢市, 藤井伸治, 近藤英生, 前田嘉信

    第40回日本造血細胞移植学会総会  2018.2.1 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • 同種造血幹細胞移植患者におけるStenotrophomonas maltophilia菌血症の死亡リスク因子の検討

    碓井喜明, 淺田騰, 近藤匠, 松田真幸, 坂本真衣子, 谷勝真, 藤原悠紀, 佐伯恭昌, 廻勇輔, 岡本幸代, 西森久和, 松岡賢市, 藤井伸治, 近藤英生, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集  2017.12.11 

     More details

    Language:Japanese  

    researchmap

  • Distinct Contribution By Perivascular Niche Cells in Hematopoietic Stem Cell Maintenance International conference

    Asada N, Kunisaki Y, Nagasawa T, Frenette P.S

    2015.12.5 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

▼display all

Awards

  • Outstanding Abstract Achievement Award

    2015.12   American Society of Hematology  

    Noboru Asada

     More details

  • 岡山医学会賞

    2014.6   岡山医学会  

    淺田騰

     More details

  • Abstract Achievement Award

    2011.12   American Society of Hematology  

    Noboru Asada

     More details

Research Projects

  • 神経操作と生体イメージングによる白血病-神経-循環連関の解明

    Grant number:21H03810  2021.04 - 2024.03

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    淺田 騰, 檜山 武史

      More details

    Grant amount:\17290000 ( Direct expense: \13300000 、 Indirect expense:\3990000 )

    白血病は血液悪性腫瘍の代表であり、罹患年齢層は若年から老年と幅広く、治療抵抗/難治性であることが多い。白血病の病態には、血液細胞自体への遺伝学的異常に加え、骨髄内の非血液細胞により構成される微小環境である“白血病ニッチ”による腫瘍化の促進、腫瘍維持機構が重要であることがわかっている。本研究では、骨髄あるいは他の臓器で白血病細胞が神経や血管といった環境とどのように関わり合いながら増殖し進展していくかを画像解析によって目で見える形で明らかにし、さらに、遺伝学的神経操作の技術により、骨髄や他臓器に分布する末梢神経の活動を制御することで新たな白血病の治療方法とできるかを検討する。今年度は、白血病動態画像解析に用いる、骨髄内の血管、血管周囲間質細胞ならびに自律神経(交感神経・副交感神経)や感覚神経を可視化できる遺伝子改変マウスを導入・交配し、骨髄を中心とした三次元的臓器画像の取得を行なった。また、マウスの生体内で白血病を発症させるモデル動物の作製のため、MLL-AF9融合遺伝子をマウス骨髄細胞に遺伝子導入し、マウス生体内で白血病を作製することができる急性骨髄性白血病モデルマウスの作製を行った。この白血病細胞は蛍光蛋白(GFP)を発現するため、“見える”白血病細胞として使用でき、今後、上記の血管可視化マウスなどに接種することによって白血病と周囲の環境細胞との関わりを解析し、白血病-神経-循環連関を明らかにしていく。

    researchmap

  • 神経ペプチドNPYによる同種造血幹細胞移植後の非感染性呼吸器合併症治療の開発

    Grant number:21K08372  2021.04 - 2024.03

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    前田 嘉信, 宮原 信明, 淺田 騰, 藤原 英晃

      More details

    Grant amount:\4030000 ( Direct expense: \3100000 、 Indirect expense:\930000 )

    同種造血幹細胞移植後に発症する閉塞性細気管支炎などの非感染性呼吸器合併症は,予後が極めて不良であり病態解明も不十分である。これまでの基礎研究によりTh17細胞などのリンパ球に加え,マクロファージも病態に関与することが示唆された。神経ペプチドNPYは神経終末のみならず肺マクロファージからも産生され,肺線維化に関与する可能性がある。
    Neuropeptide Y (NPY)は中枢神経系に広く発現する神経ペプチドで,神経系の細胞のみならず血球系細胞や気道上皮細胞にも発現している。NPYのY1受容体は血液系細胞を中心に広く分布し,Y1受容体からのシグナルによりT細胞はTh2反応に誘導される。
    ハウスダスト誘導アレルギー性気道炎症モデルを用いて,NPY 欠損マウスではアレルギー性気道炎症,気道過敏性に関与する気道および全身のTh2 反応が減弱することを明らかにした。また、ブレオマイシン誘導特発性肺線維症モデルを用いて,NPY 欠損マウスでは肺線維化が増悪することを見出した。
    次に、マイナー抗原不一致のドナーB6 →レシピエントB10.BRの系を用いた移植後の閉塞性細気管支炎(BO)マウスモデルを確立した。レシピエントマウスは、組織学的に線維化も含め評価し(NIH Image Analysis system),肺機能 (FlexiVent small-animal ventilator SCIREQ, Montreal, PQ, Canada)も合わせて測定し、BOに合致する結果が確認された。B6のNPY欠損マウス(Charles River)はすでに繁殖し使用可能であり,B10.BRにもバッククロスも進んでいる。

    researchmap

  • The clarification of bone formation and absorption mechanism in the bone marrow microenvironment

    Grant number:19H03842  2019.04 - 2022.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    Ono Mitsuaki

      More details

    Grant amount:\17550000 ( Direct expense: \13500000 、 Indirect expense:\4050000 )

    BMP-2 has been widely studied for its potent ability to induce osteoblast differentiation and ectopic bone formation, and is already in clinical use worldwide. On the other hand, we have shown that BMP-2 inhibits bone formation in the bone marrow. However, the mechanism by which BMP-2 suppresses bone formation remains unclear. Therefore, we analyzed the detail of BMP-2 induced bone. Single cell RNA-seq analysis revealed that BMP-2-induced bone formed bone marrow with hematopoietic function. These results suggest that BMP-2 has the ability to regenerate bone marrow as an organ, and may suppress bone formation in the bone marrow in order to reserve space for hematopoiesis.

    researchmap

  • Regulation of the hematopoietic system by the innate lymphoid cells

    Grant number:19K17830  2019.04 - 2021.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists  Grant-in-Aid for Early-Career Scientists

    Asada Noboru

      More details

    Grant amount:\4290000 ( Direct expense: \3300000 、 Indirect expense:\990000 )

    Innate lymphoid cells (referred to as ILC) control organ functions by releasing various cytokines, although they are in small numbers in each organ. In this study, we analyzed the ILC in the bone marrow, which is the site of ILC development and differentiation, and examined the function of the ILC in the regulation of hematopoiesis. Among various ILCs, ILC-2P, which is a precursor cell of ILC-2, is abundant in the bone marrow, and these cells remain even after irradiation. We found a temporary increase prior to the recovery of the hematopoietic stem cells (cells that are the source of all hematopoietic cells) after the myelosuppression induced by irradiation. These results suggest that ILC-2P in bone marrow plays a role for promoting the recovery of hematopoiesis after hematopoietic stresses (anticancer agents, radiation, etc.) by some mechanism.

    researchmap

  • Research for the elucidation of the mechanism of bone marrow GVHD focused on perivascular hematopoietic stem cell niche.

    Grant number:17H06882  2017.08 - 2019.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Research Activity Start-up  Grant-in-Aid for Research Activity Start-up

    Asada Noboru, MAEDA yoshinobu, MATSUOKA ken-ichi

      More details

    Grant amount:\2730000 ( Direct expense: \2100000 、 Indirect expense:\630000 )

    An acute GVHD mice model was created using C3H/HeJ as a donor and either C57BL/6 or Nestin-GFP transgenic mice that can label perivascular niche cells as a recipient. Analysis of bone marrow at 21 days after transplantation indicates that the number of HSCs is significantly smaller in the allogeneic (allo) group than in the syngeneic (syn) group, suggesting that recovery of HSCs is impaired by the alloimmune response after transplantation. The number of perivascular niche cells were also significantly reduced in the allo group compared to the syn group. Moreover, the perivascular Nestin-GFP+ cells were also impaired the same as the GVHD model using wild-type mice. The decrease of niche cells was confirmed by analysis by both FACS and imaging. The present study revealed that the acute immune response after bone marrow transplantation also significantly damages perivascular niche cells.

    researchmap

 

Class subject in charge

  • Introduction to Clinical Medicine and Dentistry (2023academic year) Concentration  - その他

  • Practicals: Hematology, Oncology and Respiratory Medicine (2023academic year) special  - その他

  • Research Projects: Hematology, Oncology and Respiratory Medicine (2023academic year) special  - その他

  • Internal Medicine (2)(Core Clinical Practice) (2023academic year) special  - その他

  • Research Projects and Practicals: Hematology, Oncology and Respiratory Medicine I (2023academic year) special  - その他

  • Lecture and Research Projects: Hematology, Oncology and Respiratory Medicine I (2023academic year) special  - その他

  • Research Projects and Practicals: Hematology, Oncology and Respiratory Medicine II (2023academic year) special  - その他

  • Lecture and Research Projects: Hematology, Oncology and Respiratory Medicine II (2023academic year) special  - その他

  • Hematology (2023academic year) special  - その他

  • Respiratory Medicine (2022academic year) special  - その他

  • Introduction to Clinical Medicine and Dentistry (2022academic year) Concentration  - その他

  • Internal Medicine (2)(Core Clinical Practice) (2022academic year) special  - その他

  • Research Projects and Practicals: Hematology, Oncology and Respiratory Medicine I (2022academic year) special  - その他

  • Lecture and Research Projects: Hematology, Oncology and Respiratory Medicine I (2022academic year) special  - その他

  • Research Projects and Practicals: Hematology, Oncology and Respiratory Medicine II (2022academic year) special  - その他

  • Lecture and Research Projects: Hematology, Oncology and Respiratory Medicine II (2022academic year) special  - その他

  • Hematology (2022academic year) special  - その他

  • Respiratory Medicine (2021academic year) special  - その他

  • Introduction to Clinical Medicine and Dentistry (2021academic year) Concentration  - その他

  • Internal Medicine (2)(Core Clinical Practice) (2021academic year) special  - その他

  • Research Projects and Practicals: Hematology, Oncology and Respiratory Medicine I (2021academic year) special  - その他

  • Lecture and Research Projects: Hematology, Oncology and Respiratory Medicine I (2021academic year) special  - その他

  • Research Projects and Practicals: Hematology, Oncology and Respiratory Medicine II (2021academic year) special  - その他

  • Lecture and Research Projects: Hematology, Oncology and Respiratory Medicine II (2021academic year) special  - その他

  • Hematology (2021academic year) special  - その他

  • Introduction to Clinical Medicine and Dentistry (2020academic year) Concentration  - その他

  • Internal Medicine (2)(Core Clinical Practice) (2020academic year) special  - その他

  • Hematology (2020academic year) special  - その他

▼display all